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Abstract 
 The demand for hip arthroplasty is increasing rapidly due to a combination of an 
aging population as well as an increasing level of obesity in the country. The purpose of this 
study is to evaluate the risks and benefits of arthroplasty for patients of different obesity 
classes. The first two parts were to use a systematic review with meta-analysis and 
retrospective chart review to quantify the risks and benefits in different obesity classes. The 
third part was to perform a cost-effectiveness analysis to weight the balance between the two. 
We found that higher obesity classes are at higher risk of complications and comparable 
improvement after an arthroplasty. Our cost-effectiveness analysis determined that greater 
obesity levels had a higher incremental cost-effectiveness ratio than lower obesity levels, but 
was within generally used willingness-to-pay thresholds. In conclusion, patients of all obesity 
levels have a greater benefit to cost ratio for total hip arthroplasty. 
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Chapter 1  
1 Introduction  
1.1 Obesity 
The World Health Organization (WHO) defines obesity as an abnormal or excessive fat 
accumulation that presents a risk to health.1 The common metric used to measure obesity 
is body mass index (BMI). It is calculated by dividing weight (kg) by the square of height 
(m) resulting in units of kg/m2. The WHO categorizes individuals into different weight 
classifications based on the magnitude of the BMI: underweight (BMI<18.5), normal 
weight (BMI 18.50-24.99), overweight (BMI≥25.00), obese class I (BMI = 30.00-34.99), 
obese class II (BMI = 35.00-39.99), and obese class III (BMI≥40.00).2 Due to major 
clinical differences between the higher BMIs in obese patients, the medical literature 
commonly further subcategorizes them as severe obesity (BMI > 35), morbid obesity 
(BMI > 40), and super (morbid) obesity (BMI > 50).2–4 There are limitations to the use of 
BMI to quantify obesity as it does not account for muscle versus fat mass, physical 
characteristics, or racial differences. Another issue is that it does not account for the 
distribution of fat since it can be central (abdominal) or peripheral (hip and thighs). 
Central obesity is more strongly associated with diabetes, heart disease, and metabolic 
syndrome.5 However, due to BMI's ease of calculation and widespread adoption, it has 
become the standard for quantifying obesity. 
The prevalence and severity of obesity has been increasing rapidly across the world. In 
the early 1980s, obese individuals composed only 10.8% of Canada's and 14.7% of the 
United States' adult population. By 2004-2006, those numbers doubled to 23.1% in 
Canada and 33.9% in the United States6 (Figure 1-1). Similarly, European countries have 
reported dramatic increases in obesity rates over the last few decades. France had a rate 
of 6.3% in 1980, which increased to 16.9% in 2007, while the United Kingdom went 
from 6.7% in 1982 to 22.7% in 2002.6 The increase in obesity rates is related to the rise 
in conditions such as heart disease, stroke, high blood pressure, diabetes, sleep apnea, and 
arthritis.6 These associated conditions drive increased medical resource use since their 
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direct medical costs can be 36%-100% greater than the non-obese patient. It is estimated 
in the United States that the annual healthcare costs due to obesity is $86-147 billion. 
Obesity also leads to significant indirect costs, and it is estimated to cost $3.38-$6.38 
billion from reduced productivity and absenteeism.7 The direct and indirect costs of 
obesity in Canada are estimated to be between $4.6 and $7.1 billion.8   
 
Figure 1-1: Trends in Overweight and Obesity Levels in the United States 
Reprinted with permission from Derman, P. B., Fabricant, P. D. & David, G. The Role of 
Overweight and Obesity in Relation to the More Rapid Growth of Total Knee 
Arthroplasty Volume Compared with Total Hip Arthroplasty Volume. J. Bone Joint Surg. 
Am. 96, 922–928 (2014).9 
 
1.2 Obesity and Arthritis 
Arthritis is a term for all processes that lead to swelling, stiffness, and pain in a joint. The 
most common form is osteoarthritis, which is when cartilage, the smooth coating at the 
end of bones, becomes worn out leading to the rubbing of bone on bone at the joint.10 
Obesity predisposes patients to develop osteoarthritic changes in their hip and knee 
joints. Obese individuals have been found to have a 60% greater likelihood of having 
arthritis relative to the non-obese population.11 Evidence has demonstrated that increased 
weight leads to increased biomechanical forces through the joints placing the individual 
at a higher risk for wear and tear resulting in arthritis.12 Biomechanical studies suggest 
that the hip experiences forces of three times body weight with single leg stance and the 
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knee experiences forces four to five time bodyweight with activity.13 Another explanation 
for the increased rate of arthritis development in obese individuals is their altered 
metabolic state.15 Increased fat stores can release pro-inflammatory cytokines such as 
TNFa and IL-6 which can cause cartilage destruction or alter cartilage metabolism even 
in cases of osteoarthritis.14,16 Obesity also alters adipokine hormones including leptin and 
adiponectin, which can have a pro-inflammatory effect. Through incompletely 
understood pathways, it is thought these changes have deleterious effects on cartilage.17 
Regardless of the exact etiology for developing arthritis, higher levels of obesity are 
associated with an increased risk for undergoing a THA. A study by Bourne et al. 
reported that obesity increased the relative risk for THA: 1.00 for non-obese, 1.92 for 
overweight, 3.41 for obesity class I, 5.24 for obesity class II, and 8.56 for obesity class 
III.18 Similar results were found in Australia, with a relative risk of 1.26 per every 5 
kg/m2 increase in BMI (95% confidence interval (CI): 1.15-1.38).14 
Higher BMI levels also increase the risk of undergoing an arthroplasty at a younger age. 
Vulcano et al. found that each BMI obesity class was associated with having an 
arthroplasty two years earlier than the next higher BMI class.19 Gandhi et al. found that 
patients who had a BMI greater than 35 kg/m2 underwent a THA seven years earlier than 
an individual with BMI less than 25 kg/m2.20 Another study reported an even earlier age 
for undergoing arthroplasty, with morbidly-obese patients undergoing a THA 10 years 
before those with a normal BMI.21 
Concurrently with the growing obesity epidemic, there has been a rapid increase in 
arthroplasties performed. Derman et al. reported that both THAs and TKAs have 
increased dramatically from 1993 to 2009 (Figure 1-2).9 Derman evaluated factors that 
affected the supply and demand of arthroplasty to identify the source of this growth, and 
they determined obesity played a significant role in this increase.9  
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Figure 1-2: Trend in THA and TKA Procedures in the United States from 1993-
2009 
Reprinted with permission from Derman, P. B., Fabricant, P. D. & David, G. The Role of 
Overweight and Obesity in Relation to the More Rapid Growth of Total Knee 
Arthroplasty Volume Compared with Total Hip Arthroplasty Volume. J. Bone Joint Surg. 
Am. 96, 922–928 (2014).9 
As a result of increasing rates of obesity, obese patients now comprise a greater 
proportion of the arthroplasty population. Fehring et al. reported that 52.1% of their 
arthroplasty patients were obese in 2005, and those numbers are higher now.22 Singh and 
Lewallen reported that the severity of obesity is also increasing. Patients with a BMI 
greater than 40 comprised 6.3% of the primary THAs performed in 2002-2005, which is 
up from 2.3% in 1993-1995.23 In addition, arthroplasty rates are projected to increase 
rapidly in the coming years. Kurtz et al. projected in the United States that relative to 
2005, there will be a 174% increase in the number of THAs performed by 2030.24 The 
rapid growth of obesity appears to be inextricably tied together with the rapid growth of 
THA, and that raises the question of whether obese patients experience similar outcomes 
following THA as non-obese patients. 
1.3 Benefits of Arthroplasty for Obese Patients 
There has been debate in the orthopedic community regarding how much obese patients 
benefit from arthroplasty. Although evidence shows improvement in functional outcome 
following arthroplasty25–28, there is controversy whether they achieve the same level of 
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function as non-obese patients. McLawhorn et al. reported EQ-5D scores for normal, 
overweight, obese class I, obese class II, and obese class III patients.25 The EQ-5D is a 
standardized questionnaire to measure generalized health related quality of life. They 
found that preoperatively, the obese class II (0.58±0.01) and III (0.54±0.03) patients had 
lower utility scores than the normal weight patients (0.66±0.01). The lower scores 
persisted two years after a THA with normal at 0.90±0.004, obese class II at 0.84±0.01, 
and obese class III at 0.85±0.02, however the change scores were similar for all obesity 
classifications. In fact, the obese class III cohort had a greater improvement following 
THA compared to the normal weight cohort (0.31±0.02 vs 0.24±0.01, p = 0.0216).25 
Other studies also suggest that despite having lower preoperative functional scores, obese 
patients achieve the same degree of improvement after an arthroplasty.29,30 Although 
obese patients clearly benefit from a THA, this comes with increased risks and 
complications from surgery.  
1.4 Risks of Arthroplasty for Obese Patients 
The main concern for performing arthroplasty in obese patients is the risk for 
perioperative complications. One contributing factor is that obese patients tend to have a 
greater number of comorbidities. Odum et al. found nearly 30% of obese patients had 
greater than 3 comorbidities compared to only 7% of the non-obese populations.31 The 
comorbidities that are more common among obese patients include diabetes, metabolic 
syndrome, and obstructive sleep apnea. Multiple studies have demonstrated that these 
conditions are associated with a greater risk of perioperative complications that can lead 
to an increased length of stay.32–36 Kremers et al. reported an increased length of stay of 
0.16 days for every 5 kg/m2 over BMI 30.37  
Infection is one of the most devastating complications following arthroplasty, and in an 
obese patient the risk of infection is increased. Wagner et al. reported the hazard ratios 
relative to the normal weight population for infection across a range of BMIs: obese class 
I 1.6 (95% CI: 1.2-2.2), obese class II 1.9 (95% CI: 1.3-2.8), and obese class III 4.1 (95% 
CI: 2.8-5.9).38 Similarly, they also found the risk for revision is higher relative to the 
normal weight cohort: obese class I HR= 0.9 (95% CI: 0.8-1.01), obese class II HR=0.9 
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(95% CI: 0.7-1.1), and obese class III is 1.3 (95% CI: 1.04-1.7).38 This study suggests 
that patients with a BMI greater than 40 are at a dramatically greater risk of infection by 
more than 4 times and revision by 30% compared to normal weight patients.38 Due to the 
greater number of comorbidities among obese patients and increased risk of perioperative 
complications, existing evidence suggests the overall cost of performing THA in this 
population is also significantly greater. 
1.5 Economic Considerations 
Many studies have reported increased overall costs in higher BMI cohorts. For example, 
Kim found that hospital costs for morbidly obese patients were 9% greater for primary 
THA compared to non-obese patients.39 Dowsey et al. reported that the index 
hospitalization costs AUS$128.91 (95% CI: $34.53-$223.28) more per unit of BMI 
increase.40 Kremers et al. reported that every 5 units of BMI over 30 kg/m2 is associated 
with a US$500 increase in hospital costs and US$900 greater 90-day costs after a primary 
THA.37 The increasing demand for the procedure has led to changes in healthcare policy 
placing a greater emphasis on decreasing costs for arthroplasty care. Some healthcare 
systems are now instituting bundled payment plans for arthroplasty procedures where 
physicians and hospitals will be held financially accountable for complications within 90 
days of a surgery. The majority of these bundled payment initiatives do not risk stratify 
patients.41 Given the known increased risks and costs of obese arthroplasty patients, many 
providers have arbitrarily chosen specific BMI cut-off levels (anywhere from 35-45) to 
determine eligibility for an arthroplasty procedure. These cut-off levels were determined 
only considering the short-term risk of complications and increased costs without any 
evaluation of the long-term benefit of arthroplasty in obese patients. There have been no 
cost-effectiveness analysis published for obese arthroplasty patients to guide this decision 
to justify a cut-off threshold. A more thorough evaluation of both the risks and benefits 
over the long-term is warranted prior to instituting BMI cut-off levels.  
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1.6 Rationale for Study 
With increasing obesity levels and resulting rising demand for arthroplasty procedures, it 
is crucial to evaluate the most efficient allocation of resources to achieve optimal patient 
outcomes. Due to greater comorbidities and increased risk of complications, performing 
arthroplasty for obese patients is more expensive. However, given that obese patients also 
experience significant benefit from the procedure, there is a need to evaluate the value of 
THA in this population. With increasing population weight, more people are in higher 
BMI groups (BMI>45 and 50) that weren’t developed when the WHO BMI categories 
were initially defined. Subjective surgical experience and reporting in the literature 
suggests that the higher BMI categories carry with them a higher complication rate and 
subsequent cost. There is a need to evaluate the cohorts at the extreme end (BMI above 
45 or 50) and understand how to appropriately establish risk and stratify costs. The 
objective of this research is to evaluate the magnitude of the benefits and risks associated 
with primary THA for patients with varying BMI levels (including patients with a BMI 
above 45 or 50) and to estimate both short term (90-day) and long term economic 
implications.  
1.7 Economic Analysis Tools 
One of the tools to conduct health economic analysis is the Markov model, which is a 
diagram representing all the possible health states an individual can have and the possible 
paths to change health states.42 Each of the health states and transitions between them 
have a cost and/or utility score (a metric to quantify the health of an individual with 1 
representing perfect health and 0 death) tied to it. There is a probability associated with 
each of the transitions and the model is cycled a predetermined number of times to 
simulate the individual passing through different health states over the time period of 
interest. By tallying the costs and utility scores over the time period of interest, the total 
costs and utilities can be quantified. If a time period of one year is utilized, the utilities 
can be simply summed to have units of quality-adjusted life years (QALYs). One QALY 
means having a utility score of 1 (perfect health) for one year. Consequently having a 
utility score of 0.5 for 2 years of a utility score of 1 for 1 year would be equivalent 
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QALYs.43 For time periods other than one year, the utility score will need to be adjusted 
for the year to calculate a QALY.  
 In cost-effectiveness analysis, generally two different treatment options are 
compared using the average cost-effectiveness ratio (ACER) or the incremental cost-
effectiveness ratio (ICER). The ACER is calculated by dividing the total cost of a 
treatment by the total QALYs it provides. Then the ACER value for the two treatment 
options are directly compared. Historically, this was the more common metric to compare 
the cost-effectiveness of treatment options. However, this approach is limited in 
situations where one treatment option provides a significant number of QALYs for a low 
cost and the other treatment provides slightly more QALYs for a much greater cost. The 
ACER value for both treatment options could be within reasonable levels, but in the 
second treatment the sizeable additional cost to get a small improvement in QALYs may 
not be justified. As a result, ICERs are the standard metric used in cost-effectiveness 
analysis currently. It is calculated by determining the incremental cost and QALY gains 
with one treatment over another and then taking the ratio. By this method, treatments that 
provide small additional QALY gains at a much higher cost can be easily identified.44 
The ICER number can be compared against different willingness-to-pay (WTP) 
thresholds to determine if the treatment is cost-effective. This WTP number is based on 
what society would determine as an appropriate cost for obtaining one additional QALY. 
There is controversy over whether or not to use this assessment. In cases where it is used, 
there is debate over how the WTP level should be determined. Commonly the WTP is 
determined based on standards set by other accepted medical interventions, such as an 
ICER of US$50,000-100,000+ for a lifetime of dialysis. As a result some studies use a 
WTP of US$50,000-100,000.45 We will apply these tools to determine the cost-
effectiveness of THA for different BMI levels. 
1.8 Study Objectives  
1) To systematically review the existing literature and determine differences in 
reoperations, aseptic and septic revisions, and change in functional outcome 
scores for various BMI categories. 
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2) To assess 90 day costs and mid-term outcome scores for the following BMI 
categories: <25, 25-29.9, 30-34.9, 35-39.9, 40-44.9, and 45+.  
3) To estimate the cost-effectiveness of THA compared to nonoperative 
management among these BMI categories over 15 years. 
  
10 
 
1.9 References 
1. WHO | What is overweight and obesity? WHO Available at: 
http://www.who.int/dietphysicalactivity/childhood_what/en/. (Accessed: 30th May 2017) 
2. Meller, M. M. et al. Risk and Cost of 90-Day Complications in Morbidly and 
Superobese Patients After Total Knee Arthroplasty. J. Arthroplasty 31, 2091–2098 
(2016). 
3. Meller, M. M. et al. Surgical Risks and Costs of Care are Greater in Patients Who 
Are Super Obese and Undergoing THA. Clin. Orthop. 474, 2472–2481 (2016). 
4. Werner, B. C., Higgins, M. D., Pehlivan, H. C., Carothers, J. T. & Browne, J. A. 
Super Obesity Is an Independent Risk Factor for Complications After Primary Total Hip 
Arthroplasty. J. Arthroplasty 32, 402–406 (2017). 
5. Aras, Ş., Üstünsoy, S. & Armutçu, F. Indices of Central and Peripheral Obesity; 
Anthropometric Measurements and Laboratory Parameters of Metabolic Syndrome and 
Thyroid Function. Balk. Med. J. 32, 414–420 (2015). 
6. WHO :: Global Database on Body Mass Index. Available at: 
http://apps.who.int/bmi/index.jsp. (Accessed: 12th February 2017) 
7. Hammond, R. A. & Levine, R. The economic impact of obesity in the United 
States. Diabetes Metab. Syndr. Obes. Targets Ther. 3, 285–295 (2010). 
8. Government of Canada, P. H. A. of C. Obesity in Canada - Healthy Living - 
Public Health Agency of Canada. (2011). Available at: http://www.phac-aspc.gc.ca/hp-
ps/hl-mvs/oic-oac/econo-eng.php. (Accessed: 17th June 2017) 
9. Derman, P. B., Fabricant, P. D. & David, G. The Role of Overweight and Obesity 
in Relation to the More Rapid Growth of Total Knee Arthroplasty Volume Compared 
with Total Hip Arthroplasty Volume. J. Bone Joint Surg. Am. 96, 922–928 (2014). 
11 
 
10. What Is Arthritis? arthritis.org Available at: http://www.arthritis.org/about-
arthritis/understanding-arthritis/what-is-arthritis.php. (Accessed: 17th June 2017) 
11. Leveille, S. G., Wee, C. C. & Iezzoni, L. I. Trends in obesity and arthritis among 
baby boomers and their predecessors, 1971-2002. Am. J. Public Health 95, 1607–1613 
(2005). 
12. Creamer, P. & Hochberg, M. C. Osteoarthritis. Lancet Lond. Engl. 350, 503–508 
(1997). 
13. Booth, R. E. Total knee arthroplasty in the obese patient: tips and quips. J. 
Arthroplasty 17, 69–70 (2002). 
14. Wang, Y. et al. Relationship between body adiposity measures and risk of 
primary knee and hip replacement for osteoarthritis: a prospective cohort study. Arthritis 
Res. Ther. 11, R31 (2009). 
15. Felson, D. T. Weight and osteoarthritis. J. Rheumatol. Suppl. 43, 7–9 (1995). 
16. Lübbeke, A., Duc, S., Garavaglia, G., Finckh, A. & Hoffmeyer, P. BMI and 
severity of clinical and radiographic signs of hip osteoarthritis. Obes. Silver Spring Md 
17, 1414–1419 (2009). 
17. King, L. K., March, L. & Anandacoomarasamy, A. Obesity & osteoarthritis. 
Indian J. Med. Res. 138, 185–193 (2013). 
18. Bourne, R., Mukhi, S., Zhu, N., Keresteci, M. & Marin, M. Role of obesity on the 
risk for total hip or knee arthroplasty. Clin. Orthop. 465, 185–188 (2007). 
19. Vulcano, E., Lee, Y.-Y., Yamany, T., Lyman, S. & Valle, A. G. D. Obese patients 
undergoing total knee arthroplasty have distinct preoperative characteristics: an 
institutional study of 4718 patients. J. Arthroplasty 28, 1125–1129 (2013). 
12 
 
20. Gandhi, R., Wasserstein, D., Razak, F., Davey, J. R. & Mahomed, N. N. BMI 
independently predicts younger age at hip and knee replacement. Obes. Silver Spring Md 
18, 2362–2366 (2010). 
21. Changulani, M., Kalairajah, Y., Peel, T. & Field, R. E. The relationship between 
obesity and the age at which hip and knee replacement is undertaken. J. Bone Joint Surg. 
Br. 90, 360–363 (2008). 
22. Fehring, T. K., Odum, S. M., Griffin, W. L., Mason, J. B. & McCoy, T. H. The 
obesity epidemic: its effect on total joint arthroplasty. J. Arthroplasty 22, 71–76 (2007). 
23. Singh, J. A. & Lewallen, D. G. Increasing obesity and comorbidity in patients 
undergoing primary total hip arthroplasty in the U.S.: a 13-year study of time trends. 
BMC Musculoskelet. Disord. 15, 441 (2014). 
24. Kurtz, S., Ong, K., Lau, E., Mowat, F. & Halpern, M. Projections of primary and 
revision hip and knee arthroplasty in the United States from 2005 to 2030. J. Bone Joint 
Surg. Am. 89, 780–785 (2007). 
25. McLawhorn, A. S. et al. Body Mass Index Class Is Independently Associated 
With Health-Related Quality of Life After Primary Total Hip Arthroplasty: An 
Institutional Registry-Based Study. J. Arthroplasty 32, 143–149 (2017). 
26. Lash, H., Hooper, G., Hooper, N. & Frampton, C. Should a Patients BMI Status 
be Used to Restrict Access to Total Hip and Knee Arthroplasty? Functional Outcomes of 
Arthroplasty Relative to BMI - Single Centre Retrospective Review. Open Orthop. J. 7, 
594–599 (2013). 
27. Issa, K. et al. Bariatric Orthopaedics: Total Hip Arthroplasty in Super-Obese 
Patients (Those with a BMI of ≥50 kg/m2). J. Bone Joint Surg. Am. 98, 180–185 (2016). 
28. Foster, S. A. et al. Effects of Obesity on Health Related Quality of Life Following 
Total Hip Arthroplasty. J. Arthroplasty 30, 1551–1554 (2015). 
13 
 
29. McCalden, R. W., Charron, K. D., MacDonald, S. J., Bourne, R. B. & Naudie, D. 
D. Does morbid obesity affect the outcome of total hip replacement?: an analysis of 3290 
THRs. J. Bone Joint Surg. Br. 93, 321–325 (2011). 
30. Rajgopal, R. et al. Outcomes and complications of total hip replacement in super-
obese patients. Bone Jt. J. 95–B, 758–763 (2013). 
31. Odum, S. M., Springer, B. D., Dennos, A. C. & Fehring, T. K. National obesity 
trends in total knee arthroplasty. J. Arthroplasty 28, 148–151 (2013). 
32. Jain, N. B., Guller, U., Pietrobon, R., Bond, T. K. & Higgins, L. D. Comorbidities 
increase complication rates in patients having arthroplasty. Clin. Orthop. 232–238 
(2005). 
33. Kandil, A., Werner, B. C., Gwathmey, W. F. & Browne, J. A. Obesity, morbid 
obesity and their related medical comorbidities are associated with increased 
complications and revision rates after unicompartmental knee arthroplasty. J. 
Arthroplasty 30, 456–460 (2015). 
34. Gage, M. J., Schwarzkopf, R., Abrouk, M. & Slover, J. D. Impact of metabolic 
syndrome on perioperative complication rates after total joint arthroplasty surgery. J. 
Arthroplasty 29, 1842–1845 (2014). 
35. Zmistowski, B. et al. Patients with uncontrolled components of metabolic 
syndrome have increased risk of complications following total joint arthroplasty. J. 
Arthroplasty 28, 904–907 (2013). 
36. Gupta, R. M., Parvizi, J., Hanssen, A. D. & Gay, P. C. Postoperative 
complications in patients with obstructive sleep apnea syndrome undergoing hip or knee 
replacement: a case-control study. Mayo Clin. Proc. 76, 897–905 (2001). 
37. Maradit Kremers, H., Visscher, S. L., Kremers, W. K., Naessens, J. M. & 
Lewallen, D. G. Obesity increases length of stay and direct medical costs in total hip 
arthroplasty. Clin. Orthop. 472, 1232–1239 (2014). 
14 
 
38. Wagner, E. R., Kamath, A. F., Fruth, K. M., Harmsen, W. S. & Berry, D. J. Effect 
of Body Mass Index on Complications and Reoperations After Total Hip Arthroplasty. J. 
Bone Joint Surg. Am. 98, 169–179 (2016). 
39. Kim, S. H. Morbid obesity and excessive hospital resource consumption for 
unilateral primary hip and knee arthroplasty. J. Arthroplasty 25, 1258–1266 (2010). 
40. Dowsey, M. M., Liew, D. & Choong, P. F. M. Economic burden of obesity in 
primary total knee arthroplasty. Arthritis Care Res. 63, 1375–1381 (2011). 
41. Comprehensive Care for Joint Replacement Model | Center for Medicare & 
Medicaid Innovation. Available at: https://innovation.cms.gov/initiatives/CJR. 
(Accessed: 12th February 2017) 
42. Wright, D. Markov Model. York Health Economics Consortium 
43. Glossary | NICE. Available at: https://www.nice.org.uk/glossary?letter=q. 
(Accessed: 9th August 2017) 
44. MHPE 441: Medical Decision Making. Available at: 
http://araw.mede.uic.edu/~alansz/courses/mhpe441/week10.html. (Accessed: 9th August 
2017) 
45. WHO | Thresholds for the cost–effectiveness of interventions: alternative 
approaches. WHO Available at: http://www.who.int/bulletin/volumes/93/2/14-
138206/en/. (Accessed: 9th August 2017) 
 
 
 
 
15 
 
Chapter 2  
2 A Systematic Review and Meta-Analysis of Revision 
Rates and Functional Outcome Scores for Severely, 
Morbidly, and Super-Obese Primary Total Hip 
Arthroplasty Patients  
2.1 Introduction 
The demand for hip and knee arthroplasty is rising rapidly due to a combination of an 
aging population as well as an increasing level of obesity in the US and Canada.1–4 Obese 
patients (BMI>30) who undergo an arthroplasty report significant improvements in pain, 
function, and activity levels after the procedure.5 However, obese patients are at a greater 
risk for perioperative complications, infections, revision,6–8 and increased costs of care.9 
All patients with a BMI greater than 30 are not same. The degree of obesity impacts the 
level of risk and benefits for the individual. Since both the extent and degree of obesity is 
rising worldwide, studies have begun investigating the impact of having a BMI greater 
than 35, 40, 45, and even 50 on outcomes following arthroplasty.8,10–14 Current 
studies10,12–14 tend to have small sample sizes followed for a few years post surgery, or 
larger patient populations analyzed for short follow up times of a few months.8 Prior 
systematic reviews and meta-analyses15–17 focusing on outcomes of total hip arthroplasty 
with obesity have only evaluated outcomes in patients with a BMI greater than 30. These 
studies may be missing important differences in outcomes with higher BMIs. For 
example, Wagner et al.18 found that revision rates are only significantly greater than the 
non-obese cohort at a BMI greater than 40. We therefore propose a systematic review and 
meta-analysis assessing the outcomes for patients following THA separated into BMI 
categories greater than 30.  
The purpose of this study is to perform a systematic review and meta-analysis to 
determine differences in functional scores, reoperations, and aseptic and septic revisions 
following THA in severely (BMI>35), morbidly (BMI>40), and super-obese (BMI>50) 
patients versus a non-obese BMI population (BMI<25). We hypothesized that there 
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would be an increased risk for reoperations, aseptic, and septic revisions for the higher 
BMI categories, while the functional scores would be comparable. 
2.2 Methods 
We conducted a systematic search of the online bibliographic databases Medline (1946 to 
week 3 of August 2016), AMED (1985 to August 2016), Ovid Healthstar (1966 to 
August 2016), and Embase (1947 to week 3 of August 2016) to identify studies 
evaluating outcomes between varying BMI categories. We used database appropriate 
search terms including a combination of synonyms for obesity (obesity, body-mass index, 
overweight) linked with hip arthroplasty or replacement found in the abstract, title, text 
words, or keywords. The search was limited to articles written in the English language. 
The reference lists of included studies were reviewed to identify any additional studies 
that would be eligible. Three pairs of reviewers assessed the titles and abstracts of articles 
found in the initial search for eligibility. Eligible studies included those that 1) evaluated 
primary total hip arthroplasty outcomes by BMI, 2) BMI was evaluated as a categorical 
variable and the highest BMI category was at minimum 35 or above, and 3) included the 
outcomes of interest (reoperations, revision (aseptic and septic) and change scores 
(preoperative to postoperative) of functional scores). All titles and abstracts that met the 
eligibility criteria and any marked uncertain were obtained in full text for further review. 
Each abstract and full-text article were independently reviewed by two authors using the 
same eligibility criteria. Any discrepancies were discussed between the authors until a 
consensus was reached. In cases of duplicate reports on the same patient sample, we 
chose to include the most recent study. We calculated a Kappa statistic to provide a 
measure of interobserver agreement for study eligibility. The Kappa statistic is a standard 
tool used to measure the degree of interobserver agreement beyond chance alone.19 
A quality assessment of the included studies was performed with the ROBINS-I tool for 
non-randomized studies developed by the Cochrane Bias Methods Group.20 This tool 
assesses internal validity based on seven criteria including 1) bias due to confounding, 2) 
bias in selection of participants into the study, 3) bias in classification of interventions, 4) 
bias due to deviations from intended interventions, 5) bias due to missing data, 6) bias in 
measurement of outcomes, and 7) bias in selection of the reported result. For bias due to 
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confounding we assigned a low risk of bias to studies with a prospective design and 
retrospective studies with matched cohorts or analysis controlling for baseline factors, 
while a moderate risk of bias was attributed for other retrospective studies. For selection 
bias, studies were considered at serious risk of bias if they excluded those that did not 
meet a minimum follow-up requirement (ex. retrospective study requiring 1 year follow-
up therefore missing patients with early complications). For bias in classifications of 
interventions, we considered how BMI was measured. If BMI was directly measured it 
was defined as low, if obtained retrospectively from a patient chart defined as moderate, 
or if patient self reported defined as serious. For deviations from intended intervention, 
we assessed the risk of bias based on whether there was differential treatment between 
the BMI cohorts. For bias due to missing data, if studies had less than 15% missing data 
and similar distributions across BMI categories it was graded as a moderate risk of bias.20 
If the proportion of missing data was greater than 15% or there was differential missing 
data it was considered a serious risk of bias. For bias in outcome measurement, we 
considered items such as subjective or objective outcome, blinding and differential 
outcome assessment between BMI categories. Bias in reported results was based on 
whether all planned analyses proposed in the methods were included in the results. 
Information about specific databases/registries gained from other literature sources were 
utilized to evaluate the risk of bias in other papers using the same data source if data was 
missing or not clear in the original report. 
For the meta-analysis, results were categorized into severely (BMI>35), morbidly 
(BMI>40), and super-obese (BMI>50) patients, and were compared to a non-obese 
(BMI<25) group within the same paper. If the paper did not have a BMI less than 25 
group, then the smallest equivalent BMI group was used for comparison. Data was 
extracted from all eligible studies. In addition to recording author name, study title, 
journal name, issue, and page numbers; we extracted number of patients, patient 
demographics, means, standard deviations, range, 95% confidence intervals, interquartile 
range and change scores for functional outcomes and event rates for reoperations and 
aseptic and septic revisions. If the change in functional outcome scores was not provided, 
they were calculated based on the difference in means from preoperative to postoperative. 
In these cases, the standard deviation of change scores were estimated to be the same as 
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for comparable studies with the same functional outcome scores that provided change 
scores with standard deviation. The order of preference for functional outcome scores 
were: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), 
Oxford Hip Score, Harris Hip Score, and EuroQol (EQ-5D). Authors were contacted 
when data in the paper was unclear or missing. Meta-analysis was performed using a 
random effects model where appropriate. Change scores were converted to standardized 
mean difference for comparison across studies using different outcome measures. 
Relative risks were used as summary measures for reoperation and revision rates. We 
calculated pooled estimates and 95% confidence intervals (CI) for both the standardized 
mean difference and relative risk. 
We performed heterogeneity calculations using the I2 statistic on all outcomes. Sensitivity 
analyses for short (less than a year) and longer (equal to or greater than a year) follow-up 
were performed for all outcomes. All calculations were performed with RevMan software 
(RevMan 5.3, Cochrane Collaboration, London, United Kingdom). 
2.3 Results 
We identified 1,692 potentially relevant articles from the literature search. We screened 
448 full-text articles and 33 studies met the eligibility criteria and were included in the 
final analyses (Figure 2-1). Inter-rater agreement was good-to-excellent for determining 
eligibility for titles and abstracts (Κ=0.84) and full-text articles (Κ=0.84). 
Our quality assessment identified 2 prospective studies, 6 retrospective studies with 
matched comparison group, and 2 retrospective studies with controlled analysis (Table 2-
1). The remaining 23 studies were retrospective studies without a matched comparison 
group or controlled analysis. Bias due to selection and missing data were the most 
frequent. Lack of information provided in reports made bias in classification of BMI and 
deviation from intended intervention difficult to evaluate. Overall, for the majority of 
studies and categories, the studies had moderate to serious risk of bias (Table 2-2). 
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Figure 2-1: Flowchart of Article Selection 
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Table 2-1: Demographics of Included Studies 
Demographics of Included Studies. R = Retrospective, P = Prospective, M = Matched cohort, C = Controlled analysis, N/A = 
information not available in paper 
 Non-Obese Cohort Obese Cohort(s) 
Study 
Study 
Type BMI N Age 
Sex 
(%Female) BMI n Age Sex (%Female) 
McLawhorn et. al. (2016) 
R 18.5-25 865 66.35±0.36 70.8 35-40 186 61.90±0.65 51.6 
>=40 73 60.51±1.08 52.1 
Fu et. al. (2016) 
R, C 18.5-29.9 10997 N/A 58.6 35-39.9 2557 N/A 53.7 
>=40 1596 N/A 59.6 
Purcell et. al. (2016) R <35 1417 63.3±11.0 56.7 >=35 204 59.3±10.26 60.3 
Hanly et. al. (2016) R 18.5-25 186 67.2±13.9 54.3 >=40 39 61.4±9.6 76.9 
Walls et. al. (2015) R 18.5-40 45895 65.4±12.0 55.2 >40 3580 60.5±9.8 60.8 
Lash et. al. (2013) R <30 985 N/A N/A >35 144 N/A N/A 
Issa et. al. (2016) 
R, M 
<30 135 
55 (range: 
48-75) N/A >=50 45 
54 (range 
36-71) 
Foster et. al. (2015) R <30 274 N/A N/A >40 23 N/A N/A 
Arsoy et. al. (2014) R, M <50 84 56.7±11.6 70.0 >=50 42 56.5±12.3 72.0 
Murgatroyd et. al. (2014) R 20-24.99 1136 69.18±12.03 63.1 >40 219 59.95±10.02 62.6 
Jameson et. al. (2014) 
Cemented Stems 
R 
19-29.9 1640 74.3±7.6 62.5 >=35 321 70.7±7.4 72.3 
Jameson et. al. (2014) 
Cementless Stems 
R 
19-29.9 1738 66.7±9.6 56.3 >=35 428 62.9±9.1 58.2 
Khatod et. al. (2014) R <30 21574 N/A N/A >=35 5778 N/A N/A 
Judge et. al. (2014) 
R 18.5-25 864 N/A N/A 35-40 150 N/A N/A 
>40 47 N/A N/A 
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Table 2-1 (continued): Demographics of Included Studies 
Demographics of Included Studies. R = Retrospective, P = Prospective, M = Matched cohort, C = Controlled analysis, N/A = 
information not available in paper 
Issa et. al. (2013) 
R, M 
<25 46 N/A N/A >=50 23 
50 (range 
25-71) 55.0 
Rajgopal et. al. (2013) 
R, M 
18.5-24.9 39 
53.1 (range 
29-72) 85.0 >50 39 
53 (range 
31-72) 83.0 
Namba et. al. (2012) R 18.5-30 17569 N/A N/A >=35 4754 N/A N/A 
Jamsen et. al. (2012) 
R <25 1105 N/A N/A 35-39 559 N/A N/A 
>=40 193 N/A N/A 
Jones et. al. (2012) R <25 52 N/A N/A >=35 32 
Michalka et. al. (2012) R <30 113 67.7±13.20 58.4 >=35 21 65.4±8.96 42.9 
Lehman et. al. (1994) 
R 
20-30 142 
48 (range 
19-73) 25.4 >=40 8 
52 (range 
37-72) 25.0 
Traina et. al. (2011) R 18.5-24.9 6102 N/A 71.0 >=40 187 N/A 66.8 
McCalden et. al. (2011) 
R 
<25 647 
71.0 (range 
23.77-
95.74) 70.6 >=40 206 
59.7 (range 
26.51-
82.36) 63.6 
Chee et. al. (2010) 
R, M 
<30 55 
63.6 (range 
45-83) 77.4 
>=40 or 
>=35 with 
1 major 
comorbidity 55 
63.7 (range 
45-83) 77.4 
Dowsey et. al. (2010) P <30 277 68.6±10.8 58.1 >=40 21 65.6±10.7 85.7 
Judge et. al. (2010) R <30 623 N/A N/A >=40 11 N/A N/A 
Bennett et. al. (2010) 
R, M 
20-25 29 
61.6 (range 
43-74) 72.4 >=40 29 
61.4 (range 
42-74) 72.4 
Andrew et. al. (2008) P <30 1069 69.1±11.1 62.4 >40 18 60.6±12.3 72.2 
Dowsey et. al. (2008) R <25 301 N/A N/A >=40 44 N/A N/A 
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Table 2-1 (continued): Demographics of Included Studies 
Demographics of Included Studies. R = Retrospective, P = Prospective, M = Matched cohort, C = Controlled analysis, N/A = 
information not available in paper 
McLaughlin et. al. (2006) R 20-25 33 N/A N/A >=35 30 N/A N/A 
Namba et. al. (2005) R <=35 922 66±13 57.0 >35 149 62±9 62.0 
Jibodh et. al. (2004) R <25 51 68±12 63.0 >=40 18 59±15 78.0 
Stickles et. al. (2001) 
R <25 131 N/A N/A 35-40 51 N/A N/A 
>40 27 N/A N/A 
Werner et. al. (2016) 
R, C <30 702360 N/A 61.0 40-49.9 62556 N/A 66.3 
>=50 3244 n 72.2 
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Table 2-2: Summary of Quality Assessment of Included Studies. 1 = Low risk of bias; 2 = Moderate risk of bias; 3 = Serious risk 
of bias; NI = Not enough information to evaluate. 
 Confounding 
Selection 
of 
Participants 
in Study 
Classification 
of BMI 
Deviation 
from Intended 
Intervention 
Missing 
Data 
Measurement 
of 
Reoperation/
Aseptic/Septic 
Revisions 
Measurement 
of Functional 
Outcome 
Scores 
Selection 
of 
Reported 
Result 
McLawhorn et. al. 
(2016) 2 3 3 NI 3  2 2 
Fu et. al. (2016) 1 2 1 NI 2 1  2 
Purcell et. al. (2016) 2 2 NI 2 NI 2  2 
Hanly et. al. (2016) 2 3 2 NI NI 2  2 
Walls et. al. (2015) 2 2 1 NI 2 1  2 
Lash et. al. (2013) 2 2 NI NI 3  2 2 
Issa et. al. (2016) 1 2 2 2 NI 2 2 2 
Foster et. al. (2015) 2 3 2 NI 2  2 2 
Arsoy et. al. (2014) 1 2 1 NI 3 2 2 2 
Murgatroyd et. al. 
(2014) 2 2 NI NI 2 2  2 
Jameson et. al. (2014) 2 3 3 NI 2 2 2 2 
Khatod et. al. (2014) 2 2 2 NI 2 2  2 
Judge et. al. (2014) 2 2 NI NI 3  2 2 
Issa et. al. (2013) 1 2 NI 2 NI 2 2 2 
Rajgopal et. al. (2013) 1 2 2 2 NI 2 2 2 
Namba et. al. (2012) 2 2 2 3 NI 2  2 
Jamsen et. al. (2012) 2 3 2 2 NI 1  2 
Jones et. al. (2012) 2 2 2 2 2  2 2 
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Table 2-2 (continued): Summary of Quality Assessment of Included Studies. 1 = Low risk of bias; 2 = Moderate risk of bias; 3 = 
Serious risk of bias; NI = Not enough information to evaluate. 
Michalka et. al. (2012) 2 2 1 NI 2  2 2 
Lehman et. al. (1994) 2 3 2 NI 2 NI  2 
Traina et. al. (2011) 2 2 NI NI NI NI  2 
McCalden et. al. 
(2011) 2 3 2 2 2 2 2 2 
Chee et. al. (2010) 1 3 3 2 2 1  2 
Dowsey et. al. (2010) 1 2 1 NI 2  2 2 
Judge et. al. (2010) 2 2 NI NI 3  2 2 
Bennett et. al. (2010) 1 3 NI 2 NI 2 2 2 
Andrew et. al. (2008) 1 2 NI 2 3 2 2 2 
Dowsey et. al. (2008) 2 2 NI NI 2 2  2 
McLaughlin et. al. 
(2006) 2 2 NI 2 2 2  2 
Namba et. al. (2005) 2 2 2 NI 2 1  2 
Jibodh et. al. (2004) 2 2 NI 2 NI 2  2 
Stickles et. al. (2001) 2 3 NI NI 3  2 2 
Werner et. al. (2016) 1 2 3 NI NI 3  2 
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Figure 2-2: Reoperation Rates Across Severely, Morbidly, and Super-Obese 
Patients 
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Figure 2-3: Aseptic Revisions Rates Across Severely, Morbidly, and Super-Obese 
Patients 
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Figure 2-4: Septic Revision Rates Across Severely, Morbidly, and Super-Obese 
Patients. 
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*For the super-obese analysis, an earlier study by Issa et. al. (2013)14 is included in the 
table, but not used for the pooled calculations. A more recent paper on the same patient 
population by Issa et. al. (2016)12 was used for pooled calculations. 
 BMI>405,26,34,35,40,43–45 
 BMI>5010,12,14 
 
Figure 2-5: Change Scores for Outcome Across Severely, Morbidly, and Super-
Obese Patients 
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For risk of reoperations relative to the non-obese cohort, we found that there was an 
increased relative risk for the morbidly (2.01, 95% CI: 1.81-2.23, p<0.01) and super-
obese patients (2.62, 95% CI: 1.68-4.07, p<0.01) (Figure 2-2). The increased risk of 
reoperation for the severely-obese was not significant (1.40, 95% CI: 0.97-2.02, p=0.07). 
Exclusion of studies with short-term (less than a year) follow-up did not change the 
significance of the results for the severely-obese (1.24, 95% CI: 0.68-2.26, p=0.49) or 
super-obese (3.57, 95% CI: 1.33-9.57, p=0.01). In the case of the morbidly-obese, the 
increased risk was no longer significant (1.50, 95% CI: 0.93-2.41, p=0.10). Both the 
morbidly and super-obese patient comparisons had no heterogeneity with I2 = 0% and 
10%, respectively, the heterogeneity had minimal change with the sensitivity analysis. 
Between study heterogeneity was not reduced with sensitivity analysis for the severely-
obese patient comparison (I2 = 83% and I2 = 82% for the longer follow-up studies only).  
Aseptic revision was only reported in one study for the severely-obese patients (Figure 2-
3). That study did not show any increased risk for the severely-obese patients (0.70, 95% 
CI: 0.45-1.10, p=0.12), but each group only had about 30 patients. Similarly, there was 
no significantly increased risk of aseptic revisions for either the morbidly (1.40, 95% CI: 
0.84-2.32, p=0.20) or super-obese (1.98, 95% CI: 0.80-4.94, p=0.14) patients. All studies 
for both the morbidly and super-obese patients included longer follow-up so no additional 
sensitivity analysis was performed for this outcome. There was no heterogeneity (I2 = 
0%) for either the morbidly or super-obese analysis.  
The risk of septic revisions were found to be significantly higher for severely (3.17, 95% 
CI: 2.25-4.47, p<0.01), morbidly (9.75, 95% CI: 3.58--26.59, p<0.01), and super-obese 
patients (7.22, 95% CI: 1.51-34.60, p=0.01) (Figure 2-4). Sensitivity analysis could not 
be performed for the severely or super-obese patients, since all included studies had 
follow-up of one year or greater. After removal of the studies with short follow-up in the 
morbidly-obese patient analysis, the risk ratio was still significantly greater at 7.49 (95% 
CI: 3.85-14.57, p<0.01) and the heterogeneity was reduced from 70% to 0%. There was 
no heterogeneity (I2 = 0%) with the severely and super-obese analysis. 
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The change in functional outcome score as evaluated by standardized mean difference 
was not significantly different between the severely (0.04, 95% CI: -0.02-0.10, p=0.19), 
morbidly (0.19, 95% CI: -0.08-0.46, p=0.17), and super-obese patients (-0.12, 95% CI: -
0.57-0.33 p=0.60) with then non-obese population. Sensitivity analysis focusing on 
longer term outcomes of 1 year or more did not alter the results for the severely (0, 95% 
CI: -0.10-0.09, p=0.95) or morbidly-obese (0.15, 95% CI: -0.10-0.40, p=0.23). All 
studies included for the super-obese analysis had longer term follow up, and two reported 
worse improvement and one reported better improvement for the super-obese resulting in 
high heterogeneity for this result (I2 = 86%). There was no heterogeneity (I2 = 0%) for the 
severely-obese analysis. Sensitivity analysis did not reduce the heterogeneity (I2 = 84% 
vs. 86%) for the morbidly-obese analysis. 
2.4 Discussion 
Our results suggest that both morbidly and super-obese populations are at a higher risk 
for reoperation following THA than the non-obese population, with the super-obese at a 
higher relative risk than the morbidly obese. All three obese groups were at a higher risk 
for septic revision than the non-obese patients, and the morbidly-obese (RR 9.75, 95% 
CI: 3.58--26.59, p<0.01) and super-obese (RR 7.22, 95% CI: 1.51-34.60, p=0.01) had a 
much higher relative risk than the severely-obese (RR 3.17, 95% CI: 2.25-4.47, p<0.01) 
patients. The severely, morbidly, and super-obese patients did not have a significant 
difference in aseptic revision or change in functional outcome scores.  
Our study did not find a greater risk of reoperation until the BMI reached the morbidly 
and super-obese groups. Wagner et al. reported similar results based on their 
retrospective study of their institution's outcomes.39 They found no significantly greater 
risk of reoperation until a BMI greater than 40, which had a hazard ratio of 1.6 (95% CI: 
1.3-2.0) relative to the non-obese. We had a comparable risk ratio of 2.01 (95% CI: 1.81-
2.23) for our morbidly-obese group. For the morbidly-obese deep infection rate, we 
reported a greater risk ratio of 9.75 (95% CI: 3.58-26.59) versus Wagner et al.'s hazard 
ratio of 4.4 (95% CI: 2.8-6.9).18 The difference in results could be partly attributed to the 
varying definitions in deep infection/septic revisions utilized by the studies included in 
the meta-analysis. Also, our sensitivity analysis examining longer term follow-up 
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demonstrated a slightly lower relative risk ratio that does include Wagner's hazard ratio in 
its confidence interval (7.49, 95% CI: 3.85-14.57). 
In recent years, there has been an increased focus on preoperative optimization prior to 
THA and TKA. It has been controversial whether, and to what degree, obesity can be 
reduced, or at least optimized. Some studies have examined the impact of both 
nonoperative and operative means of weight loss but their influence on improving 
arthroplasty outcomes has not been clearly demonstrated.46 At the same time, there is 
clear evidence that obese patients have increased costs of care and complications.47 
Consequently, some authors recommend BMI thresholds (35-45) above which an 
arthroplasty should not be offered.11,41,48 Our study clearly demonstrates that over the 
long term, severely, morbidly, and super-obese patients benefit significantly by having an 
arthroplasty with comparable change scores as the non-obese cohorts, although they also 
have varying levels of increased risks for reoperation and septic revision. This leads to 
the question of whether obese patients should be denied a procedure that provides 
significant benefit, despite the additional risks. For other chronic diseases such as 
diabetes, we do not deny those patients an arthroplasty. Instead, physicians focus on 
improving their glucose management, to optimize their perioperative outcomes. 
Unfortunately, there are no clear obesity treatments that have been demonstrated to 
improve obesity's perioperative risk profile. This issue will become even more important 
with the combined factors of increasing number of obese individuals, increasing degree 
of obesity around the world, and changing health care policy.1,47  
The limitations in this study are those common with systematic reviews and meta-
analysis; the quality of results are limited by the quality of the included studies. We did 
perform a quality analysis and found that the predominant study design was retrospective 
cohort studies, with only two prospective cohort studies, resulting in a high degree of 
either selection or missing data bias. Another limitation included varying follow-up times 
that can influence the revision rates. We did account for that in our sensitivity analysis 
and found that in only one case did it alter the significance of our results. For the super-
obese group's change score analysis, we only had three studies with one reporting a 
conflicting results. This warrants further research to better evaluate their outcome scores 
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after arthroplasty. Some studies did not have a non-obese (BMI 18.5-25) cohort for 
comparison, as a result the smallest BMI cohort was chosen for comparison. Since 
Wagner et al18 suggested that results only dramatically change above a BMI of 40, this 
likely is not an important factor for reoperations since the comparison groups had a BMI 
less than or equal to 40 (except for one study in the super-obese group, Arsoy et. al.10, 
which used a comparison group with BMI less than 50). The results for septic revision 
could be underestimated due to the differences in comparison groups. For the functional 
outcome score comparisons, we choose the outcome measures that were most commonly 
reported in the included studies, but some studies only reported one outcome measure in 
which case that was used. 
Older literature tended to categorize all patients with a BMI greater than 30 as obese, and 
prior systematic reviews15–17 have used these studies to evaluate the impact of obesity. 
However, a more granular evaluation of obesity is warranted since the risk profile of 
everyone with a BMI greater than 30 is not the same. This inspired our study to focus on 
a systematic review and meta-analysis of the studies that consider the sub-categories of 
obesity. In addition, many of the studies on higher obesity categories were limited by 
number of patients available, and we hoped to increase the power of our study by pooling 
the results of multiple studies in the meta-analysis. We found that severely, morbidly, and 
super-obese patients have comparable functional outcome score improvements to non-
obese patients, but have higher risk of reoperation and septic revision. The different 
obesity thresholds have dramatically different risk profiles that need to be accounted for 
in perioperative counseling. 
 
  
33 
 
2.5 References 
1. WHO :: Global Database on Body Mass Index. Available at: 
http://apps.who.int/bmi/index.jsp. (Accessed: 12th February 2017) 
2. Derman, P. B., Fabricant, P. D. & David, G. The Role of Overweight and Obesity 
in Relation to the More Rapid Growth of Total Knee Arthroplasty Volume Compared 
with Total Hip Arthroplasty Volume. J. Bone Joint Surg. Am. 96, 922–928 (2014). 
3. Bourne, R., Mukhi, S., Zhu, N., Keresteci, M. & Marin, M. Role of obesity on the 
risk for total hip or knee arthroplasty. Clin. Orthop. 465, 185–188 (2007). 
4. Leveille, S. G., Wee, C. C. & Iezzoni, L. I. Trends in obesity and arthritis among 
baby boomers and their predecessors, 1971-2002. Am. J. Public Health 95, 1607–1613 
(2005). 
5. McLawhorn, A. S. et al. Body Mass Index Class Is Independently Associated 
With Health-Related Quality of Life After Primary Total Hip Arthroplasty: An 
Institutional Registry-Based Study. J. Arthroplasty 32, 143–149 (2017). 
6. Ward, D. T., Metz, L. N., Horst, P. K., Kim, H. T. & Kuo, A. C. Complications of 
Morbid Obesity in Total Joint Arthroplasty: Risk Stratification Based on BMI. J. 
Arthroplasty 30, 42–46 (2015). 
7. Wallace, G. et al. The effect of body mass index on the risk of post-operative 
complications during the 6 months following total hip replacement or total knee 
replacement surgery. Osteoarthritis Cartilage 22, 918–927 (2014). 
8. Werner, B. C., Higgins, M. D., Pehlivan, H. C., Carothers, J. T. & Browne, J. A. 
Super Obesity Is an Independent Risk Factor for Complications After Primary Total Hip 
Arthroplasty. J. Arthroplasty 32, 402–406 (2017). 
9. Maradit Kremers, H., Visscher, S. L., Kremers, W. K., Naessens, J. M. & 
Lewallen, D. G. Obesity increases length of stay and direct medical costs in total hip 
arthroplasty. Clin. Orthop. 472, 1232–1239 (2014). 
34 
 
10. Arsoy, D., Woodcock, J. A., Lewallen, D. G. & Trousdale, R. T. Outcomes and 
complications following total hip arthroplasty in the super-obese patient, BMI > 50. J. 
Arthroplasty 29, 1899–1905 (2014). 
11. Schwarzkopf, R., Thompson, S. L., Adwar, S. J., Liublinska, V. & Slover, J. D. 
Postoperative complication rates in the ‘super-obese’ hip and knee arthroplasty 
population. J. Arthroplasty 27, 397–401 (2012). 
12. Issa, K. et al. Bariatric Orthopaedics: Total Hip Arthroplasty in Super-Obese 
Patients (Those with a BMI of ≥50 kg/m2). J. Bone Joint Surg. Am. 98, 180–185 (2016). 
13. Rajgopal, R. et al. Outcomes and complications of total hip replacement in super-
obese patients. Bone Jt. J. 95–B, 758–763 (2013). 
14. Issa, K. et al. Early results of total hip arthroplasty in the super-obese patients. J. 
Long. Term Eff. Med. Implants 23, 309–313 (2013). 
15. Haynes, J., Nam, D. & Barrack, R. L. Obesity in total hip arthroplasty: does it 
make a difference? Bone Jt. J. 99–B, 31–36 (2017). 
16. Liu, W. et al. The influence of obesity on primary total hip arthroplasty outcomes: 
A meta-analysis of prospective cohort studies. Orthop. Traumatol. Surg. Res. OTSR 101, 
289–296 (2015). 
17. Vincent, H. K. et al. Obesity and long term functional outcomes following 
elective total hip replacement. J. Orthop. Surg. 7, 16 (2012). 
18. Wagner, E. R., Kamath, A. F., Fruth, K. M., Harmsen, W. S. & Berry, D. J. Effect 
of Body Mass Index on Complications and Reoperations After Total Hip Arthroplasty. J. 
Bone Joint Surg. Am. 98, 169–179 (2016). 
19. McGinn, T. et al. Tips for learners of evidence-based medicine: 3. Measures of 
observer variability (kappa statistic). CMAJ Can. Med. Assoc. J. 171, 1369–1373 (2004). 
35 
 
20. ROBINS-I tool - Risk of bias tools. Available at: 
http://www.riskofbias.info/welcome/home. (Accessed: 23rd June 2017) 
21. Fu, M. C. et al. Malnutrition Increases With Obesity and Is a Stronger 
Independent Risk Factor for Postoperative Complications: A Propensity-Adjusted 
Analysis of Total Hip Arthroplasty Patients. J. Arthroplasty 31, 2415–2421 (2016). 
22. Jameson, S. S. et al. The impact of body mass index on patient reported outcome 
measures (PROMs) and complications following primary hip arthroplasty. J. 
Arthroplasty 29, 1889–1898 (2014). 
23. Khatod, M., Cafri, G., Namba, R. S., Inacio, M. C. S. & Paxton, E. W. Risk 
factors for total hip arthroplasty aseptic revision. J. Arthroplasty 29, 1412–1417 (2014). 
24. McLaughlin, J. R. & Lee, K. R. The outcome of total hip replacement in obese 
and non-obese patients at 10- to 18-years. J. Bone Joint Surg. Br. 88, 1286–1292 (2006). 
25. Purcell, R. L., Parks, N. L., Gargiulo, J. M. & Hamilton, W. G. Severely Obese 
Patients Have a Higher Risk of Infection After Direct Anterior Approach Total Hip 
Arthroplasty. J. Arthroplasty 31, 162–165 (2016). 
26. Andrew, J. G. et al. Obesity in total hip replacement. J. Bone Joint Surg. Br. 90, 
424–429 (2008). 
27. Chee, Y. H., Teoh, K. H., Sabnis, B. M., Ballantyne, J. A. & Brenkel, I. J. Total 
hip replacement in morbidly obese patients with osteoarthritis: results of a prospectively 
matched study. J. Bone Joint Surg. Br. 92, 1066–1071 (2010). 
28. Lehman, D. E., Capello, W. N. & Feinberg, J. R. Total hip arthroplasty without 
cement in obese patients. A minimum two-year clinical and radiographic follow-up 
study. J. Bone Joint Surg. Am. 76, 854–862 (1994). 
29. McCalden, R. W., Charron, K. D., MacDonald, S. J., Bourne, R. B. & Naudie, D. 
D. Does morbid obesity affect the outcome of total hip replacement?: an analysis of 3290 
THRs. J. Bone Joint Surg. Br. 93, 321–325 (2011). 
36 
 
30. Murgatroyd, S. E., Frampton, C. M. A. & Wright, M. S. The effect of body mass 
index on outcome in total hip arthroplasty: early analysis from the New Zealand Joint 
Registry. J. Arthroplasty 29, 1884–1888 (2014). 
31. Traina, F., Bordini, B., De Fine, M. & Toni, A. Patient weight more than body 
mass index influences total hip arthroplasty long term survival. Hip Int. J. Clin. Exp. Res. 
Hip Pathol. Ther. 21, 694–699 (2011). 
32. Namba, R. S., Inacio, M. C. S. & Paxton, E. W. Risk factors associated with 
surgical site infection in 30,491 primary total hip replacements. J. Bone Joint Surg. Br. 
94, 1330–1338 (2012). 
33. Namba, R. S., Paxton, L., Fithian, D. C. & Stone, M. L. Obesity and perioperative 
morbidity in total hip and total knee arthroplasty patients. J. Arthroplasty 20, 46–50 
(2005). 
34. Bennett, D., Gibson, D., O’Brien, S. & Beverland, D. E. Hip arthroplasty in 
morbidly obese patients - intra-operative and short term outcomes. Hip Int. J. Clin. Exp. 
Res. Hip Pathol. Ther. 20, 75–80 (2010). 
35. Dowsey, M. M., Liew, D., Stoney, J. D. & Choong, P. F. M. The impact of 
obesity on weight change and outcomes at 12 months in patients undergoing total hip 
arthroplasty. Med. J. Aust. 193, 17–21 (2010). 
36. Hanly, R. J., Marvi, S. K., Whitehouse, S. L. & Crawford, R. W. Morbid Obesity 
in Total Hip Arthroplasty: Redefining Outcomes for Operative Time, Length of Stay, and 
Readmission. J. Arthroplasty 31, 1949–1953 (2016). 
37. Jibodh, S. R., Gurkan, I. & Wenz, J. F. In-hospital outcome and resource use in 
hip arthroplasty: influence of body mass. Orthopedics 27, 594–601 (2004). 
38. Walls, J. D. et al. Hypoalbuminemia More Than Morbid Obesity is an 
Independent Predictor of Complications After Total Hip Arthroplasty. J. Arthroplasty 30, 
2290–2295 (2015). 
37 
 
39. Lash, H., Hooper, G., Hooper, N. & Frampton, C. Should a Patients BMI Status 
be Used to Restrict Access to Total Hip and Knee Arthroplasty? Functional Outcomes of 
Arthroplasty Relative to BMI - Single Centre Retrospective Review. Open Orthop. J. 7, 
594–599 (2013). 
40. Jones, C. A., Cox, V., Jhangri, G. S. & Suarez-Almazor, M. E. Delineating the 
impact of obesity and its relationship on recovery after total joint arthroplasties. 
Osteoarthritis Cartilage 20, 511–518 (2012). 
41. Judge, A. et al. Body mass index is not a clinically meaningful predictor of 
patient reported outcomes of primary hip replacement surgery: prospective cohort study. 
Osteoarthritis Cartilage 22, 431–439 (2014). 
42. Michalka, P. K. R. et al. The influence of obesity on early outcomes in primary 
hip arthroplasty. J. Arthroplasty 27, 391–396 (2012). 
43. Stickles, B., Phillips, L., Brox, W. T., Owens, B. & Lanzer, W. L. Defining the 
relationship between obesity and total joint arthroplasty. Obes. Res. 9, 219–223 (2001). 
44. Foster, S. A. et al. Effects of Obesity on Health Related Quality of Life Following 
Total Hip Arthroplasty. J. Arthroplasty 30, 1551–1554 (2015). 
45. Judge, A., Cooper, C., Williams, S., Dreinhoefer, K. & Dieppe, P. Patient-
reported outcomes one year after primary hip replacement in a European Collaborative 
Cohort. Arthritis Care Res. 62, 480–488 (2010). 
46. WHO :: Global Database on Body Mass Index. Available at: 
http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. (Accessed: 12th February 
2017) 
47. Inacio, M. C. S. et al. The impact of pre-operative weight loss on incidence of 
surgical site infection and readmission rates after total joint arthroplasty. J. Arthroplasty 
29, 458–464.e1 (2014). 
38 
 
48. Comprehensive Care for Joint Replacement Model | Center for Medicare & 
Medicaid Innovation. Available at: https://innovation.cms.gov/initiatives/CJR. 
(Accessed: 12th February 2017) 
49. Lübbeke, A. et al. Body mass and weight thresholds for increased prosthetic joint 
infection rates after primary total joint arthroplasty. Acta Orthop. 87, 132–138 (2016). 
 
39 
 
Chapter 3  
3 90-Day Costs, Reoperations, and Readmissions for 
Primary Total Hip Arthroplasty Patients of Varying BMI 
Levels 
3.1 Introduction 
The demand for total hip arthroplasty (THA) is increasing rapidly due to a combination 
of an aging population as well as an increasing level of obesity in the US and Canada.1,2 
Patients with a higher BMI may be at a greater risk for perioperative length of stay, 
complications, infections, and revision.3–5 Nonetheless, obese patients who undergo a 
THA report significant improvements in pain, function, and activity levels after the 
procedure.6–8 Concurrently, in the United States several payers for health care including 
both government (Medicare) and private insurance are instituting bundled payment plans 
where physicians and hospitals will be held financially accountable for complications 
within 90-days of a surgery.9 Similarly, many of the Canadian provincial healthcare 
systems have fixed budgets to perform a government established number of THAs. The 
costs of any subsequent readmission or revision as a complication of the index procedure 
are absorbed by the treating hospital. Additionally, metrics such as 30-day readmissions, 
infections and reoperation within a year are used to track hospital quality. It is 
conceivable that Canadian hospitals could be penalized for underperforming outcome 
metrics which are actually a reflection of the case acuity. When a center's quality of care 
is assessed, no metric to account for taking care of a greater number of high risk patients 
(such as obesity) is utilized. In both countries, many providers have arbitrarily chosen 
specific body mass index (BMI) levels ranging from 35-45, above which they will not 
offer arthroplasty as an option. 
Health care policy incentivizes a focus on the short-term outcomes and their economic 
implications and does not account for the longer-term benefits. Prior studies have focused 
on either the costs10 or complications11–13, or on the functional outcomes8 for different 
BMIs. We sought to more thoroughly evaluate both the risks and the benefits of 
arthroplasty for a wide range of BMIs, which can provide guidance for clinicians, 
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patients and administrators to ensure optimal care for obese and non-obese arthritic 
patients.  
The primary purpose of this study is to compare 90-day costs and mid-term functional 
score improvements following total hip arthroplasty (THA) among non-obese (BMI 18.5-
24.9), overweight (25-29.9), obese (30-34.9), severely-obese (35-39.9), morbidly-obese 
(40-44.9), and super-obese (45+) patient cohorts. We hypothesized that the 90-day costs 
would be higher for the super-obese patient population, but that those patients would 
have comparable functional score improvements relative to the other BMI groups.  
3.2 Methods 
We retrospectively reviewed our institutional database to identify patients who had 
undergone a primary THA between 2006 and 2013. Data was collected at the beginning 
of 2017. All patients who had a unilateral primary THA (with an underlying diagnosis of 
osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, or osteonecrosis) were 
included for selection into the study. Patients who had a simultaneous bilateral 
arthroplasty, acute fracture or polytrauma as indication for arthroplasty, femoral 
shortening osteotomy, or skeletal dysplasia were excluded from the study. BMI was 
calculated from heights and weights measured at the preoperative assessment and 
recorded in the database. The patients were categorized into 6 groups based on BMI 
recorded in the database: <25 (non-obese), 25-29.9 (overweight), 30-34.9 (obese), 35-
39.9 (severely-obese), 40-44.9 (morbidly-obese), and 45+ (super-obese). We used a 
sample of convenience based on the number of eligible patients in the super-obese 
category, as this was expected to be the least common. We identified 33 patients with a 
BMI categorized as super-obese and met the inclusion and exclusion criteria. Patients 
from the other BMI cohorts were then selected randomly from the entire THA cohort by 
use of a random numbers table in a 2:1 ratio relative to the super-obese cohort (66 
patients in each group, total of 363 patients). Perioperative protocols were the same for 
all BMI cohorts except for DVT prophylaxis. Low molecular weight heparin was used for 
DVT prophylaxis for the morbidly and super-obese patients, and aspirin was used for the 
other cohorts. 
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3.2.1 Outcome Measures 
Patient charts and electronic medical records were reviewed. We extracted demographic 
variables including age, sex, BMI, smoking status, Charlson comorbidity index (CCI), 
and American Society of Anesthesiologists (ASA) score. We also recorded all in-hospital 
resource use such as time in the operating room, anesthesia type, length of hospital stay, 
and perioperative complications (DVT/PE and superficial infection). For the first 90-days 
postoperative, we identified emergency room visits, reoperations, and readmissions to 
hospitals within the local region (most hospitals within a 100 kilometer radius of our 
institution). Medical records were reviewed to identify mid-term revisions rates 
(reoperation for any cause, aseptic, and septic revision). Costs were determined using unit 
costs from our institutional administrative data for all in-hospital resource utilization 
(Table 3-1). Costs for the index hospitalization, 90-day readmissions, and 90-day ER 
visits were averaged over all patients whether or not they had a readmission or ER visit. 
The 90-day costs were calculated by taking the sum of the index hospitalization, 90-day 
readmissions, and 90-day ER visits. 
Table 3-1: Unit Costs from Administrative Data 
Item Costs 
Inpatient 
PACU Stay $344.10 
Inpatient Costs (per hour) $26.13/hr 
Inpatient Meals (per hour) $1.40/hr 
PT cost (per hour) $2.47/hr 
OT cost $92.22 
Average Consults $78.85 
Average Transfusion $6.84 
Average Lab & Imaging $53.12 
Pelvis X-Ray $95.13 
Antibiotics & Foley $18.73 
Operating Room 
OR Time (per min) $16.37/min 
Anesthesia Equipment $269.04 
Average OR Packs $318.59 
Acetabular Socket $500.00 
Femoral Stem $950.00 
Femoral Head $200.00 
Liner  $800.00 
Screw $75.00 
Luque Wire $43.26 
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We also collected patient-reported outcome measures from the database. All patients 
treated at our institution complete the Harris Hip Score (HHS), Short-Form Health 
Survey (SF-12), and Western Ontario and McMaster Universities Arthritis Index 
(WOMAC) preoperatively and at each visit postoperatively. We used the preoperative 
and latest postoperative data to calculate a change score for each patient. Scores were 
scaled such that lower scores meant worse function and higher scores meant greater 
function. Missing data due to inadequate recording in the patient chart or incomplete 
outcome questionnaires were not included in statistical analysis. The primary outcomes 
of interest were 90-day costs and midterm change scores. Secondary outcomes are 
perioperative outcomes, 90-day complications, and midterm (3 year) revision rates. 
3.2.2 Statistical Analysis 
We used descriptive statistics (frequencies, means and standard deviation) to summarize 
the demographics, clinical characteristics, and outcomes. For continuous variables, 
normality was tested with the Shapiro-Wilk test. Normally distributed continuous 
variables were compared using analysis of variance (ANOVA) and non-normal 
continuous variables were compared using the nonparametric Kruskal-Wallis H test. 
Significance on these tests implied that there was a statistically significant difference 
across all six cohorts. A post-hoc Tukey's test was performed on variables that 
demonstrated a significant difference on ANOVA to identify the specific BMI cohort 
comparisons that led to the statistical difference. Categorical variables were compared 
with either a Chi Square analysis or Fisher’s exact test. Statistical significance was set at 
p < 0.05. Data were analyzed using Stata, Version 12, Software (Stata Corp LP, College 
Station, TX). 
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3.3 Results 
3.3.1 Demographics 
Table 3-2: Demographics of THA Patients by BMI Group 
Variable Body Mass Index (BMI) Group  
18.5-24.9 
Non-
Obese 
(n = 66) 
25-29.9
Overweight
(n = 66)
30-34.9
Obese
(n = 66)
35-39.9
Severely-
Obese
(n = 66)
40-44.9 
Morbidly-
Obese 
(n = 66) 
45+
Super-
Obese
(n = 33) p-value 
Age 
(mean±standard 
deviation) 66.7±12.9 68.2±11.1 65.2±12.1 62.8±12.1 59.0±10.7 57.1±9.1 <0.01 
Sex (%Female) 69.7 65.2 45.5 56.1 71.2 66.7 0.02 
BMI 
(mean±standard 
deviation) 22.2±2.3 27.4±1.3 32.2±1.3 37.2±1.3 42.3±1.4 50.0±4.5 <0.01 
Charlson 
Comorbidity 
Index (CCI) (%) 
0 69.7 62.1 69.7 69.7 54.5 57.6
1 22.7 25.8 22.7 18.2 34.8 24.2
2 4.5 3.0 7.6 7.6 10.6 6.1 0.03 
3 3.0 6.1 0.0 3.0 0.0 6.1
4 0.0 0.0 0.0 1.5 0.0 6.1
5 0.0 3.0 0.0 0.0 0.0 0.0
American 
Society of 
Anesthesiologists 
Score (ASA) (%) 
1 7.6 4.5 1.5 3.0 1.5 3.0
2 45.5 45.5 50.0 28.8 15.2 6.1 <0.01 
3 39.4 47.0 43.9 60.6 75.8 57.6
4 7.6 3.0 4.5 7.6 7.6 33.3
Smoking (%) 16.7 9.1 7.6 9.1 7.6 3.0 0.31 
The demographics of the study participants are reported in Table 3-2. There was a 
statistically significant difference in age across the groups (p < 0.01). In particular, the 
morbidly and super-obese patients were significantly younger than the non-obese (p < 
0.01 and p < 0.01, respectively), overweight (p < 0.01 and p < 0.01, respectively), and 
obese groups (p = 0.03 and p = 0.02, respectively). There were significant differences in 
CCI (p = 0.03) and ASA (p < 0.01) across the BMI groups. The higher BMI categories 
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had more patients with ASA scores of 3 and 4 than 1 and 2. No significant difference was 
found in smoking rates across the BMI cohorts (p = 0.31). 
3.3.2 Primary Outcomes 
 
Figure 3-1: 90-Day Costs Across BMI Cohorts 
At 90-days, the costs were significantly different across the BMI cohorts (p < 0.01) 
(Figure 3-1). The super-obese cohort had significantly greater costs than the four smallest 
BMI cohorts (p < 0.01 for every comparison) but not relative to the morbidly-obese (p = 
0.23). The morbidly-obese cohort had significantly higher costs than the non-obese (p = 
0.03) and the severely obese (p = 0.04) cohort. The inpatient costs were significantly 
different across the BMI cohorts (p < 0.01), and the difference in magnitude between the 
super-obese and the non-obese cohorts is approximately $1,700. By 90-days, the cost 
differential between the super-obese and the non-obese cohorts is approximately $5,300. 
The main three contributors to the cost differential are readmissions, index 
hospitalization, and treatment with fragmin for DVT prophylaxis. For HHS, SF12 MCS 
and PCS, and WOMAC, there were no significant differences in change scores across the 
BMI cohorts (p = 0.29, p = 0.47, p = 0.86, and p = 0.93, respectively).  
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3.3.3 Secondary Outcomes 
Perioperative outcomes during the inpatient stay, 90-days, and after 3 years are reported 
in Table 3-3. The time in the operating room was significantly different among the BMI 
cohorts (p < 0.01). Post-hoc analysis demonstrated that the super-obese had significantly 
longer operative time compared to all other BMI cohorts (p < 0.01, p < 0.01, p < 0.01, p = 
0.01, and p = 0.01, respectively for the non-obese to morbidly-obese). The severely-obese 
and morbidly-obese had significantly longer operative time than the non-obese cohort (p 
= 0.01 and p = 0.01, respectively). There was no statistically significant difference among 
the BMI cohorts for length of hospital stay. At 90-days, there were no significant 
differences in the superficial infection (p = 0.14), VTE (p = 0.71), ER visits (p = 0.06), or 
readmissions (p = 0.05) across all the BMI cohorts. Ninety day reoperation rates were 
significantly different among the BMI cohorts (p < 0.01) with the morbidly and super-
obese patients having dramatically more reoperations of any kind.  
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Table 3-3: Outcomes of THA Patients by BMI Group 
Variable BMI Group  
18.5-24.9 
Non-
Obese 
(n = 66) 
25-29.9
Overweight
(n = 66)
30-34.9
Obese
(n = 66)
35-39.9
Severely-
Obese
(n = 66)
40-44.9
Morbidly-
Obese
(n = 66)
45+
Super-Obese
(n = 33) p-value 
Outcomes During Hospitalization 
OR Time (min) 
(mean±standard 
deviation) 119±19 122±22 129±24 133±29 132±20 150±28 <0.01 
Anesthesia 
Spinal 72.7% 50.0% 68.2% 62.1% 63.6% 60.6% 0.27 
General 27.3% 50.0% 30.3% 36.4% 36.4% 39.4%  
Other 0.0% 0.0% 1.5% 1.5% 0.0% 0.0%  
LOS (days) 
(mean±standard 
deviation) 4.4±1.7 4.3±1.5 4.8±2.5 4.2±2.0 4.6±2.0 5.6±3.5 0.06 
Discharge to 
Extended Care 
Facility 16.7% 12.1% 12.1% 13.6% 15.2% 18.2% 0.95 
Inpatient Cost 
(mean±standard 
deviation) 
$10,002 
±1,348 
$10,000
±1,265
$10,392
±1,797
$10,102
±1,772
$10,615
±1,547
$11,704
±2,997 <0.01 
Outcomes at 90 Days 
Superficial 
Infection 3.0% 7.6% 3.0% 4.5% 13.6% 9.1% 0.14 
VTE 0.0% 1.5% 3.0% 3.0% 3.0% 0.0% 0.71 
ER Visit 12.1% 19.7% 16.7% 9.1% 16.7% 33.3% 0.06 
47 
 
Table 3-3 (continued): Outcomes of THA Patients by BMI Group 
Readmission 4.5% 4.5% 6.1% 3.0% 7.6% 21.2% 0.05 
Reoperation 0.0% 4.5% 1.5% 1.5% 6.1% 18.2% <0.01 
ER Costs 
(mean±standard 
deviation) $83±240 $158±401 $113±286 $68±229 $128±373 $211±352 0.27 
Readmission 
Costs 
(mean±standard 
deviation) $226±1110 $1,230±6,610 $641±3,711 $275±1,905 $1,399±6,796 $2,697±6,018 0.15 
Cost (including 
index 
hospitalization) 
(mean±standard 
deviation) 
$10,315 
±1,848 
$11,392
±6,936
$11,150
±4,225
$10,449
±2,119
$13,134
±7,250
$15,604
±6,783 <0.01 
Outcomes after 3 Years 
Mortality  3.0% 1.5% 7.6% 1.5% 1.5% 9.1% 0.14 
Reoperation 
Cumulative 
from Index 
surgery 3.0% 4.5% 4.5% 4.5% 10.6% 21.2% 0.03 
Aseptic 
Revision 1.5% 1.5% 3.0% 3.0% 1.5% 6.1% 0.74 
Septic Revision 1.5% 3.0% 1.5% 1.5% 7.6% 18.2% <0.01 
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Table 3-4: Functional Outcome Scores of THA Patients by BMI Group 
Variable BMI Group  
(mean±standard 
deviation) 
18.5-
24.9 
Non-
Obese 
(n = 66) 
25-29.9
Overweight
(n = 66)
30-34.9
Obese
(n = 66)
35-39.9
Severely-
Obese
(n = 66)
40-44.9 
Morbidly-
Obese 
(n = 66) 
45+ 
Super-
Obese 
(n = 33) p-value 
HHS      
Preoperative 54±11 46±12 50±10 44±12 42±12  39±17 <0.01 
Postoperative 95±7 92±10 91±12 87±16 88±12 84±14 <0.01 
Change 40±12 44±15 40±16 44±20 49±14 40±17 0.29 
SF12 MCS      
Preoperative 51±11 51±10 53±11 49±12 48±12 46±12 0.06 
Postoperative 54±9 55±8 54±10 52±10 52±11 49±14 0.06 
Change 3±13 4±8 1±12 2±12 6±13 3±14 0.47 
SF12 PCS     
Preoperative 31±9 29±8 29±8 29±7 27±6 25±6 <0.01 
Postoperative 43±12 40±12 41±12 39±11 37±13 35±10 0.01 
Change 12±13 12±12 11±12 11±12 9±12 11±10 0.86 
WOMAC      
Preoperative 43±18 40±16 42±18 39±14 36±16 35±15 0.11 
Postoperative 85±18 76±23 83±18 76±22 73±22 70±23 <0.01 
Change 41±23 37±23 40±24 38±25 37±25 39±24 0.93 
Outcomes after 3 years demonstrated no significant difference in mortality (p = 0.14) or 
aseptic revisions across the cohorts (p = 0.74). Reoperation (p = 0.03) and septic revision 
(p < 0.01) rates were significantly different across the BMI cohorts. The super-obese had 
greater cumulative reoperation and septic revision rates compared to the non-obese 
cohort (21.2% vs 3.0%, p = 0.01 and 18.2% vs 1.5%, p = 0.01, respectively).  
3.4 Discussion 
Obesity is not a simple binary comorbidity that can be evaluated as being above or below 
a BMI of 30. The degree of obesity plays an influential role in the risk of perioperative 
complications and costs of care. Given that health policy in many healthcare systems in 
the developed world, including both the United States and Canada, focus on the short-
term costs (such as 90-days), one of our primary objectives was to focus on the 90-day 
costs of care for various BMI cohorts. We found that in the short-term, 90-day costs were 
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much higher for the morbidly-obese (>25% higher) and super-obese (>50%) cohorts than 
the non-obese cohort. The focus on the short-term risks should not divert attention from 
the potential mid-term benefits and they need to be stratified by BMI as well. We found 
that the change scores for HHS, SF12 MCS and PCS, and WOMAC were comparable 
across all BMI cohorts.  
Our costing analysis was based on the costs at a Canadian hospital, which generally has 
lower costs compared to the United States healthcare systems. Kremers et al. also 
reported their costs in the United States across multiple BMI cohorts and found that costs 
were relatively stable for BMIs ranging from 18.5 to 40, but above 40 the costs started to 
increase.10 The cost of their non-obese group at 90-days postoperative was approximately 
$20,000. Our results for the non-obese cohort were half as much, largely owing to the 
lower costs of care in Canada. We also found a more dramatic increase in the costs for 
the morbidly-obese and super-obese of 25-50% over the non-obese, while Kremers et 
al.10 had only a 5-10% premium for the same cohorts relative to the non-obese. In our 
study, the three main factors driving the increased costs were readmissions, index 
hospitalization, and DVT prophylaxis differences. Kremers et al.10 did not report the 
readmission rate or differences in DVT prophylaxis for their BMI cohorts. Our study had 
a 90-day reoperation rate of 6.1% in the morbidly-obese and 18.2% in the super-obese 
cohorts. Our readmission rates are comparable to those reported in the literature. In a 
meta-analysis, Ramkumar et al.17 reported a 90-day readmission rate of 7.7% after a 
THA. Our readmission rates were lower than that for all BMI groups with the exception 
of the super-obese cohort. 
We also found that the degree of improvement in outcome scores were comparable across 
the BMI cohorts. McLawhorn et al. examined EQ-5D scores (a measure of health status 
utility, frequently used for cost-effectiveness) across different BMI cohorts and reported 
that their larger BMI cohorts had comparable or greater improvements than their non-
obese cohort.8 Other studies report that the various obesity categories (ranging from 
severely-obese to super-obese) have comparable outcome score improvements as non-
obese cohorts.4,6,7,14–16 The potential for greater improvement in higher obesity classes 
may be due to their lower preoperative scores. Surgeons may delay surgical intervention 
50 
 
for the morbidly and super-obese patients because of their BMI. During the time it takes 
for these patients to identify a surgeon willing to perform their procedure, their function 
may deteriorate leading to a lower preoperative score than a patient who is at a lower 
obesity level. Consequently, an arthroplasty may lead to a larger improvement in 
outcome.  
Our study had a much higher risk for revision than was reported by Wagner et al.3 They 
reported a hazard ratio of 1.6 for reoperation for the BMI>40 cohort versus the BMI 18.5-
25 cohort, and no significant difference in risk for reoperation for other obese categories 
with a BMI<40. Similarly, we found no significant difference in reoperation in the 
overweight, obese, and severely-obese cohorts versus the non-obese cohort. Compared to 
the non-obese, our relative risk was greater in the morbidly-obese by over three times and 
for the super-obese by over seven times. This differential is likely driven by the fact that 
all patients with a BMI above 40 are not the same. A BMI over 45 or 50 is at a much 
higher risk for revision than a BMI just over 40 (Chapter 2).  
Bariatric surgery and other nonoperative weight loss measures have been proposed to 
assist morbidly and super-obese patients to attain a lower BMI and hopefully lead to a 
lower risk profile and cost. Additionally, a potential benefit of weight loss is that hip 
arthritis symptoms may improve sufficiently that an arthroplasty may not be needed at 
that time. Research to date has provided conflicting evidence on the impact of bariatric 
surgery prior to arthroplasty with some reports suggesting no improvement,18–20 other 
studies suggesting lower complication rates,13,21 and others reporting higher complication 
rates for the arthroplasty.22,23 Nonoperative weight loss treatments have not been very 
successful for weight loss for patients with a BMI over 40. Huffaker and Giori24 
conducted a retrospective study of a structured nonoperative weight loss program, and 
found that only 17% of patients with a BMI over 40 lost enough weight to bring their 
BMI below 40. Of the patients with a BMI over 45, less than 10% of patients reached that 
same goal. In addition, nonoperative weight loss options have not been shown to improve 
the complication profile for arthroplasty. There are also concerns that weight loss puts 
patients in a catabolic state leading to poorer healing and higher risk of infections and 
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wound complications.25 As of yet, there are no clear pathways to improve the 
perioperative risk profile of morbidly and super-obese patients. 
Morbidly and super-obese are at highest risk for losing access to arthroplasty despite their 
comparable improvements in functional outcomes. In both the US and Canadian 
healthcare systems, the economic incentives are to provide arthroplasty care for those 
who would be the cheapest to care for since there is no risk adjusted reimbursement. As 
well, worldwide, many hospitals are scored based on their reoperation and readmission 
profile, and their annual arthroplasty volumes and budget may be affected by their 
reported outcomes. By operating on more morbidly or super-obese patients their outcome 
metrics may suffer and consequently could be penalized with lower funding for 
arthroplasty. Concurrently, in the US, surgeons are starting to be rated based on the 
complication profile including one published by Propublica26 that does not account for 
patient risks. US News and World Report is planning to publish an arthroplasty surgeon 
rating based on outcomes in the Fall of 2017. It remains to be seen whether it will 
account for the risk profile of patients.27 Due to a multitude of reasons, both surgeons and 
hospitals are being incentivized to focus only on the short term risks regardless of the 
potential longer term benefits. This jeopardizes arthroplasty access for morbidly and 
super-obese patients when they have no clear pathway to either improve their symptoms 
or improve their risk profile. 
One of the limitations of our study is that it is a retrospective chart review for most of the 
reported outcomes. We did have prospectively collected data for functional outcome 
scores, but other results were obtained from a review of the electronic medical records. 
As the regional tertiary arthroplasty center, we tend to capture most 
complications/revisions, but we could have underestimated events that did not get 
referred back to our institution. Another limitation of our study relates to the low 
frequency of events such as revision and VTEs, where we may have had too few patients 
to be powered to detect a true difference. Consequently, we were only able to detect a 
difference for the super-obese group. In addition, owing to the small sample sizes for 
each cohort, the results may be affected by outliers. Furthermore, as a study from a single 
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tertiary care institution in Canada, our results may not be generalizable to community 
institutions or those outside of Canada.  
A strength of this study is that our institution is a regional tertiary referral center for 
arthroplasty. Nearly all readmissions, ER visits, and subsequent revisions are transferred 
to or taken care of at our hospital. We also have access to an electronic records sharing 
system, which allows us to capture any visits or readmissions to all the hospitals within 
our region (most hospitals within a 100 kilometer radius of our institution).  
In conclusion, the morbidly-obese and super-obese total hip arthroplasty patients incur 
greater costs during the first 90-days than the non-obese cohort. All BMI cohorts have 
clinically significant improvements in function that are comparable to the non-obese 
cohort. Owing to the combined pressures on hospitals and surgeons in North American 
and many healthcare systems in the developed world, there will be a high risk that the 
morbidly-obese and super-obese will lose access to arthroplasty care due to their higher 
90-day risks and costs. Health care policies do not account for the longer-term potential 
benefits of arthroplasty. Preoperative health optimization of obesity is an important topic 
of future research, but as of now we do not have an obvious method to achieve it. In the 
interim, thorough preoperative counseling of morbidly-obese and super-obese patients is 
warranted, but arbitrary restrictions should not be used to deny arthroplasty access since 
these patients have no effective alternatives and demonstrate equivalent progress to 
patients in lower BMI levels and have clinically significant functional improvements. 
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Chapter 4  
4 Cost-Effectiveness of Total Hip Arthroplasty versus 
Nonoperative Management in Non-obese, Overweight, 
Obese, Severely-Obese, Morbidly-Obese, and Super-
Obese Patients  
4.1 Introduction 
Currently, there are about 250,000 total hip arthroplasties (THAs) performed each year in 
the United States. Those numbers are projected to increase to 572,000 by 2030.1 The 
demand is increasing rapidly due to a combination of an aging population and an 
increasing level of obesity in the country.2,3 Not all obese individuals (BMI>30) have the 
same risk profiles with surgery. Higher BMI (i.e. BMI>40 and BMI>50) have a greater 
risk for perioperative complications, infections, and revision,4–6 which leads to higher 
costs of care.7 Both the United States and Canada have healthcare policies that pay a 
fixed amount for taking care of an arthroplasty patient, which typically does not account 
for the increased risks and costs of patients with comorbidities. In addition to the 
financial risks, both providers and hospitals are commonly evaluated on quality metrics 
that frequently do not account for the risk profile of their patients. In the metrics that do 
account for risk profile, they likely do not adequately adjust for the risk.8,9 Physicians and 
hospitals may be penalized by caring for higher risk patients such as extremely obese 
individuals. As a result many providers have arbitrarily chosen specific BMI levels 
(ranging from 35-45) at which they will not offer arthroplasty. These thresholds do not 
account for the long-term benefits of arthroplasty over the expected lifetime of the 
implant. Patients at all obesity levels have been shown to have significant improvements 
in pain, function, and activity levels after an arthroplasty.10–12 The alternative 
nonoperative options for hip arthritis can mitigate symptoms, but do not correct the 
underlying pathology which can further progress.13 The question arises whether THA is 
cost-effective relative to nonoperative management over a longer time horizon after 
accounting for the risks and benefits related to BMI.  
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The purpose of our study is to estimate the cost-effectiveness of performing a THA 
versus nonoperative management (NM) for non-obese (BMI 18.5-24.9), overweight (25-
29.9), obese (30-34.9), severely-obese (35-39.9), morbidly-obese (40-49.9), and super-
obese (50+) cohorts. We hypothesize that although the higher BMI cohorts will 
experience greater costs, the additional expense would be justified by significant 
improvements in quality of life compared to nonoperative care. 
4.2 Methods 
 
Figure 4-1: Markov decision model 
We constructed a Markov model (Figure 4-1) with Excel 2007 to compare the costs and 
quality-adjusted life years (QALYs) of NM and THA for six BMI cohorts (non-obese 
(BMI 18.5-24.9), overweight (25-29.9), obese (30-34.9), severely-obese (35-39.9), 
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morbidly-obese (40-49.9), and super-obese (50+)). Patients entering the model were 
assumed to have maximized nonoperative management and would be candidates for a 
THA. Consequently, those that entered the NM treatment arm would continue at the same 
functional level until the natural history of hip arthritis progressed to a worse state or they 
died. The THA treatment arm assumed the patient either does well following surgery, or 
has a complication requiring a revision. The patient can have up to two revisions prior to 
transitioning to a chronically failed arthroplasty state. Transition probabilities, health-
related quality of life weights, and costs for each health state in each BMI cohort were 
obtained from the literature (Table 4-1 to 4-4). Given the differences in prices in the US 
and Canada, we conducted separate analyses for the US and Canadian cost data. An 
annual discount rate of 3% was applied to all costs and utilities. 
4.2.1 Transition Probabilities 
The base-case annualized probabilities for conversion of a primary to revision 1 state and 
revision 1 state to revision 2 state were calculated from the 2016 Australian Registry, 
which reported an 8% risk for revision at 15 years for primary THA and 20% risk at 10 
years for the first revision.14 There were no published estimates for the probability of a 
chronically failed revision, and we assumed a 1.5% greater absolute annualized risk than 
revision 1 to revision 2. The relative risks were scaled up for the higher BMI cohorts 
based on the results of our meta-analysis (Chapter 2) and Wagner et. al.15 The 2007 
Australian Registry reported a hazard ratio of 1.383 for increased risk of mortality with a 
revision18 which we used to calculate the mortality for revision 2 and a failed 
arthroplasty. The same mortality rates were used across all BMI cohorts. The literature 
suggests that obese patients undergo arthroplasty at a younger age than a non-obese 
individual, but generally have more comorbidities that balances out their lower mortality 
risk from younger age.19–21 Prior studies of nonoperative arthritis management reported a 
risk for arthritis progression of 3.33%16-6%.17 Arthritis in higher BMI categories likely 
progresses faster than the lower BMI categories. Since literature comparing the rate of 
progression across BMI levels was not identified, we used the conservative 3.33% 
parameter for our model for all BMI cohorts, which would favor the NM treatment. 
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Table 4-1: Transition Probabilities for Surgical and Nonoperative Model 
Health 
State 
Base Case Probability Reference 
Non-
Obese 
Overweight Obese Severely-
Obese 
Morbidly-
Obese 
Super-
Obese 
Primary to 
Revision 1 
0.51% 0.51% 0.51% 0.72% 1.03% 2.00% 2016 
Australian 
Registry,14 
Wagner et. 
al.,15 meta-
analysis, 
assumption 
Revision 1 
to Revision 
2 
1.84% 1.84% 1.84% 2.58% 3.70% 5.06% 2016 
Australian 
Registry,14 
Wagner et. 
al.,15 meta-
analysis, 
assumption 
Revision 2 
to Failure 
3.34% 3.34% 3.34% 4.68% 6.71% 9.18% Assumption 
Progression 
of Hip 
Arthritis 
3.33% Chang et. 
al.16, Mota et. 
al.17 
Mortality 
of Primary 
THA 
2.35% 2016 
Australian 
Registry14 
Mortality 
of Revision 
1 
3.33% 2007 
Australian 
Registry18 
Mortality 
of Revision 
2 
4.60% Assumption 
Mortality 
of Failed 
6.36% Assumption 
4.2.2 Utilities 
McLawhorn et. al. reported the preoperative and postoperative utility scores for hip 
arthritis across a range of BMI classes that corresponded to our BMI cohorts.10 They did 
not have a super-obese group, nor did any from our systematic review that measured 
utility scores. We therefore extrapolated the trend found in McLawhorn et. al.'s study10 
for this cohort based on the trend across their BMI cohorts. Utility scores after a revision 
were obtained from Postler et. al.22, which we used as the non-obese utility score. For the 
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other BMI cohorts' post revision utility score, we assumed a similar decrease in utility as 
was reported for the primary utility scores in McLawhorn et. al.10 We assumed revision 2 
resulted in 90% the utility of revision 1.23 We assumed that arthritis that has progressed 
would have the same percentage decrease from preoperative utility as reported in the 
literature for all patients in general (not specified by BMI).16,17 Larger BMI cohorts likely 
would have a greater worsening in utility scores than the non-obese cohorts, but due to a 
lack of literature on the topic we used the conservative assumption that they had the same 
degree of worsening. 
Table 4-2: Utility Values for Surgical and Nonoperative Model 
Health State Base Case Utility Reference 
Non-
Obese 
Overweight Obese Severely-
Obese 
Morbidly-
Obese 
Super-
Obese 
Preoperative 0.66 0.66 0.62 0.58 0.54 0.5 McLawhorn 
et. al.10  
Arthritis 
Progression 
0.36 0.36 0.33 0.31 0.29 0.27 Mota et. al.,17 
Chang et. 
al.16 
Primary 
THA 
0.9 0.89 0.87 0.84 0.85 0.83 McLawhorn 
et. al.10 
Revision 1 0.8 0.79 0.77 0.74 0.75 0.73 Postler et. 
al.,22 
Assumption 
Revision 2 0.72 0.71 0.69 0.67 0.68 0.66 McLawhorn 
et. al.,23 
Assumption 
Failed 0.5 0.49 0.47 0.44 0.45 0.43 Postler et. 
al.,22 
Assumption 
4.2.3 Costs 
US Costs for primary THA and revision 1 were obtained from Kremers et. al. 90-day cost 
of care for different BMI levels, which are in 2010 US dollars.7 The Canadian costs for a 
primary THA were based on our retrospective costing study looking at 90-day costs at 
our institution, which was calculated in 2017 Canadian dollars (Chapter 3). Since we did 
not have costing data for super-obese (BMI>50) patients and revisions by BMI category, 
we assumed a similar scaling in costs relative to the other groups reported in Kremers et. 
al.7 For revision 2 in both the US and Canadian costs, we assumed that it cost 10% more 
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than revision 123 Based on US literature, we estimated annual cost of follow up for 
arthroplasty care of $581 in 2012 US dollars, as reported in Bedair et. al.25 This was 
converted to 2017 Canadian dollars by using purchasing power parities and adjusting for 
inflation. It has been reported that the costs of nonoperative arthritis care in the quarter 
prior to an arthroplasty can be US$2,094-3,100,24 while another study reported a median 
annual cost of $1,630 in 2002 Canadian dollars.26 For the US base-case annual NM cost, 
we used the value of $1,733 (converting the median annual cost in Canadian dollars to 
US dollars with purchasing power parities and then accounting for inflation for 2017 US 
dollars), and tested a wider distribution in sensitivity analyses. Gupta et. al.26 reported the 
annual direct medical costs hip arthritis in Canadian dollars, which was used for the 
Canadian costs after adjusting for inflation. Only the direct costs of medical care for an 
arthritic hip were accounted for in the model. All costs were inflation adjusted for 2017 
values. Indirect costs were not included. 
Table 4-3: US Costs for Surgical and Nonoperative Model 
Health State Base Case Cost Reference 
Non-
Obese 
Overweight Obese Severely-
Obese 
Morbidly-
Obese 
Super-
Obese 
Primary 
THA 
$22,672 
±1,386 
$21,509 
±5,202 
$21,220
±3,169 
$22,590 
±1,589 
$24,069 
±5,438 
$25,190 
±5,699 
Kremers et. 
al.7 
Revision 1 $30,750 
±1,880 
$30,070 
±7,273 
$30,579
±4,566 
$32,253 
±2,269 
$30,710 
±6,947 
$40,748 
±9,218 
Kremers et. 
al.7 
Revision 2 $33,825 
±2,068 
$33,077 
±8,000 
$33,638 
±5,023 
$35,479 
±2,496 
$33,781 
±7,643 
$44,823 
±10,140 
McLawhorn 
et. al.23 
Annual 
Nonoperative 
Care 
$2,128±1,000 Chang et. 
al.,16 Berger 
et. al.,24 
Gupta et. 
al.26   
Annual 
follow up of 
primary and 
revision 
arthroplasties 
$622 ±400 Chang et. 
al.16, Bedair 
et. al.25 
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Table 4-4: Canadian Costs for Surgical and Nonoperative Model 
Health State Base Case Cost Reference 
Non-
Obese 
Overweight Obese Severely-
Obese 
Morbidly-
Obese 
Super-
Obese 
Primary 
THA 
$10,315 
±1,848 
$11,392 
±6,936 
$11,150 
±4,225
$10,449 
±2,119 
$13,134 
±7,250 
$13,765 
±7,598 
Chapter 3 
Revision 1 $13,990 
±2,506 
$15,926 
±9.697 
$16,068
±6,088
$14,919 
±3,025 
$16,781 
±9,263 
$22,267 
±12,291 
Chapter 3, 
Kremers et. 
al.7 
Revision 2 $15,389 
±2,757 
$17,519 
±10,666 
$17,674
±6,697
$16,411 
±3,328 
$18,460 
±10,190 
$24,493 
±13,520 
McLawhorn 
et. al.23 
Annual 
Nonoperative 
Care 
$1,733±1,000 Chang et. 
al.,16 Berger 
et. al.,24 
Gupta et. 
al.26   
Annual 
follow up of 
primary and 
revision 
arthroplasties 
$798 ±400 Chang et. 
al.16, Bedair 
et. al.25 
4.2.4 Analysis 
The model was simulated for a 15 year time period with each cycle lasting one year. A 15 
year time period was chosen in order to have the longest time period for which reliable 
parameter data was available. We calculated the incremental cost-effectiveness ratio 
(ICER) for THA versus NM for each of the six BMI cohorts in both a US and Canadian 
system. To determine model robustness with the base-case parameters, one-way threshold 
sensitivity analyses were performed to determine the point at which the ICER exceeded 
the willingness to pay threshold of $25,000/QALY (USD) for the US analysis and 
$10,000/QALY (CAD) for the Canadian analysis. These values were chosen since the 
current average payment for the US Medicare bundled payment system is $25,565 (USD) 
and approximately $10,000 (CAD) in Canada.27 In addition, a Monte Carlo probabilistic 
sensitivity analysis was performed with the upper and lower bounds reported in Tables 4-
1 to 4-4. We ran 10,000 iterations for the sensitivity analysis. For the costs a gamma 
distribution was used and for transition probabilities and utilities a beta distribution was 
used. Distribution parameters were calculated using the method of moments.23,28 
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4.3 Results 
4.3.1 US Cost Analysis 
Table 4-5: US Base Case Results 
BMI Group 
Nonoperative 
Cost 
Nonoperative 
QALY 
Incremental 
Cost 
Incremental 
QALY ICER 
Non-Obese  $21,390  6.00  $18,096  2.99  $6,043  
Overweight  $21,390  6.00  $16,699  2.89  $5,770  
Obese  $21,390  5.64  $16,585  3.06  $5,425  
Severely-
Obese  $21,390  5.27  $22,866  3.10  $7,382  
Morbidly-
Obese  $21,390  4.91  $29,408  3.53  $8,338  
Super-Obese  $21,390  4.55  $59,705  3.59  $16,651  
 
With the US base case all BMI cohorts had ICERs less than $17,000/QALY (Table 4-5). 
The super-obese had the highest ICER of $16,651/QALY, while the obese had the lowest 
ICER of $5,425/QALY. All the other BMI cohorts had ICERs from $5,700 to $8,400 for 
the base-case.  
 
Figure 4-2: US Incremental Costs vs Incremental QALYs for THA over 
Nonoperative Management for Different BMI Cohorts 
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Table 4-6: US One-Way Sensitivity Threshold Analysis for ICER>$25,000, base case 
values are in parenthesis 
 BMI Category 
Parameter Non-
Obese 
Overweigh
t 
Obese Severely-
Obese 
Morbidly
-Obese 
Super-
Obese 
Transition 
Probabilitie
s 
      
Primary to 
Revision 1 
>3.33% 
(0.51%) 
>3.33% 
(0.51%) 
>3.52% 
(0.51%) 
>3.36% 
(0.72%) 
>4.16% 
(1.03%) 
>3.26% 
(2.00%) 
Revision 1 
to Revision 
2 
- - - - - - 
Revision 2 
to Failed 
Arthroplast
y 
- - - - - - 
Primary 
Mortality 
>22.19% 
(2.35%) 
>22.62% 
(2.35%) 
>23.90% 
(2.35%) 
>21.53% 
(2.35%) 
>21.92% 
(2.35%) 
>12.45% 
(2.35%) 
Revision 1 
Mortality 
- - - - - - 
Revision 2 
Mortality 
- - - - - - 
Failed 
Arthroplast
y Mortality 
- - - - - - 
Arthritis 
Progression 
- - - - - - 
Utilities       
Primary 
Arthroplast
y 
<0.67 
(0.90) 
<0.66 
(0.89) 
<0.62 
(0.87) 
<0.61 
(0.84) 
<0.60 
(0.85) 
<0.69 
(0.83) 
Revision 1 - - - - - - 
Revision 2 - - - - - - 
Failed 
Arthroplast
y 
- - - - - - 
Preoperativ
e Arthritis 
>0.91 
(0.66) 
>0.90 
(0.66) 
>0.88 
(0.62) 
>0.82 
(0.58) 
>0.80 
(0.54) 
>0.63 
(0.50) 
Costs       
Primary >$79,436 
($22,672) 
>$77,161 
($21,509) 
>$81,060 
($21,220) 
>$77,165 
($22,590) 
>$82,832 
($24,069
) 
>$55,125 
($25,190
) 
Revision 1 >$208,725 
($30,750) 
>$204,558 
($30,070) 
>$218,198 
($30,579) 
>$158,437 
($32,253) 
>$131,55
1 
>$69,949 
($40,748
66 
 
($30,710
) 
) 
Revision 2 >$2,546,7
07  
($33,825) 
>$2,496,7
28 
($33,077) 
>$2,682,6
93 
($33,638) 
>$1,344,3
63 
($35,479) 
>$796,43
8 
($33,781
) 
>$214,14
4 
($44,823
) 
Annual 
Arthroplast
y Follow-
up 
>$6,278 
($622) 
>$6,168 
($622) 
>$6,58 
($622) 
>$6,064 
($622) 
>$6,488 
($622) 
>$3,620 
($622) 
Annual 
Nonoperati
ve Care 
- - - - - - 
 
Our model was sensitive to the following parameters (the threshold was exceeded with a 
transition or utility number between 0 and 1, or any non-negative cost value): transition 
from primary to revision 1, mortality of primary THA, utility scores for primary THA, 
utility scores for preoperative arthritis, and costs of primary, revision 1, revision 2, and 
annual arthroplasty follow-up (Table 4-6). The sensitivity analysis demonstrated that the 
model was stable to a wide-range of parameters. The most critical parameter in the model 
is the probability of transition from primary to revision 1. The one-way sensitivity 
analysis threshold for the super-obese was 3.26% which is close to the 2% base case 
predicted for the super-obese group's annualized revision rate. This means that the results 
for the super-obese are extremely dependent on their risk of revision. Another important 
parameter is the preoperative utility score of a super-obese patient. If their preoperative 
utility is greater than 0.63, then a THA would not be cost-effective at a $25,000/QALY 
threshold. In order to significantly change our conclusions, the other parameters 
identified by the sensitivity analysis would require values dramatically different from the 
base case that would not be realistic. For example, the mortality rate would need to be ten 
times that reported in the literature. 
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Figure 4-3: Plot of US Monte Carlo Simulation of Incremental Costs and QALYs 
 
Figure 4-4: Percentage of Cases that Are Cost-Effective by Willingness-to-Pay 
Threshold in US Monte Carlo Simulation 
Our probabilistic sensitivity analysis demonstrated that, in the vast majority of 
simulations, performing a THA would be cost-effective at a willingness-to-pay threshold 
of $30,000/QALY (Figure 4-3 & 4-4). We used a broad range of parameter values (based 
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on the gamma and beta distributions as noted in the methods) for our simulations to 
demonstrate the robustness of the results of our model, and they show with a willingness-
to-pay threshold of $30,000/QALY, THA is cost-effective across all BMI groups. At that 
threshold, the model found THA cost-effective in comparison to NM for 100% of the 
non-obese, overweight, annd severely-obese simulations, 99.99% of obese simulations, 
99.96% of morbidly-obese simulations, and 96.65% of super-obese simulations. 
4.3.2 Canadian Cost Analysis 
Table 4-7: Canadian Base Case Results 
BMI Group 
Nonoperative 
Cost 
Nonoperative 
QALY 
Incremental 
Cost 
Incremental 
QALY ICER 
Non-Obese  $17,420  6.00  $5,713  2.99  $1,908  
Overweight  $17,420  6.00  $7,456  2.89  $2,576  
Obese  $17,420  5.64  $7,263  3.06  $2,376  
Severely-
Obese  $17,420  5.27  $8,169  3.10  $2,637  
Morbidly-
Obese  $17,420  4.91  $14,909  3.53  $4,227  
Super-Obese  $17,420  4.55  $31,468  3.59  $8,776  
 
The base-case Canadian model found that all BMI cohorts had an ICER below 
$10,000/QALY (Table 4-7). The super-obese cohort had the largest ICER for THA over 
NM of $8,776/QALY, while the other cohorts had an ICER ranging from $1,900-
4,300/QALY.  
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Figure 4-5: Canadian Incremental Costs vs Incremental QALYs for THA over 
Nonoperative Management for Different BMI Cohorts 
Table 4-8:Canadian One-Way Sensitivity Threshold Analysis for ICER>$10,000 
 BMI Category 
Parameter Non-Obese Overweight Obese Severely-
Obese 
Morbidly-
Obese 
Super-
Obese 
Transition 
Probabilities 
      
Primary to 
Revision 1 
>3.18% 
(0.51%) 
>2.56% 
(0.51%) 
>2.73% 
(0.51%) 
>3.12% 
(0.72%) 
>2.98% 
(1.03%) 
>2.33% 
(2.00%) 
Revision 1 to 
Revision 2 
- - - - - - 
Revision 2 to 
Failed 
Arthroplasty 
- - - - - - 
Primary 
Mortality 
>21.13% 
(2.35%) 
>18.20% 
(2.35%) 
>19.46% 
(2.35%) 
>19.89% 
(2.35%) 
>15.74% 
(2.35%) 
>5.20% 
(2.35%) 
Revision 1 
Mortality 
- - - - - - 
Revision 2 
Mortality 
- - - - - - 
Failed 
Arthroplasty 
Mortality 
- - - - - - 
Arthritis 
Progression 
- - - - - - 
Utilities       
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Primary 
Arthroplasty 
<0.65 
(0.90) 
<0.67 
(0.89) 
<0.63 
(0.87) 
<0.60 
(0.84) 
<0.63 
(0.85) 
<0.78 
(0.83) 
Revision 1 - - - - - - 
Revision 2 - - - - - - 
Failed 
Arthroplasty 
- - - - -  
Preoperative 
Arthritis 
>0.93 
(0.66) 
>0.90 
(0.66) 
>0.88 
(0.62) 
>0.83 
(0.58) 
>0.76 
(0.54) 
>0.55 
(0.50) 
Costs       
Primary >$34,546 
($10,315) 
>$32,877 
($11,392) 
>$34,457 
($11,150) 
>$33,257 
($10,449) 
>$33,493 
($13,134) 
>$18,153 
($13,765)
Revision 1 >$89,961 
($13,990) 
>$83,287 
($15,926) 
>$89,144 
($16,068) 
>$67,654 
($14,919) 
>$51,719 
($16,781) 
>$26,547 
($22,267)
Revision 2 >$1,088,049 
($15,389) 
>$968,611 
($17,519) 
>$1,049,462
($17,674) 
>$563,417
($16,411) 
>$282,695 
($18,460) 
>$49,313 
($24,493)
Annual 
Arthroplasty 
Follow-up 
>$3,212 
($798) 
>$2,939 
($798) 
>$3,120 
($798) 
>$3,072 
($798) 
>$2,830 
($798) 
>$1,238 
($798) 
Annual 
Nonoperative 
Care 
-  - - - 
 
 
- <$1,296 
($1,733) 
 
Our one-way sensitivity analysis for the Canadian costs identified the following 
parameters as critical to the model: transition from primary to revision 1, mortality of 
primary THA, utility scores for primary THA, utility scores for preoperative arthritis, and 
costs of primary, revision 1, revision 2, and annual arthroplasty follow-up (Table 4-8). 
Given the lower ICER threshold used for this analysis, the results of the super-obese 
group analysis was most sensitive to the primary to revision 1 transition, preoperative and 
primary arthroplasty utility, and costs for primary, revision 1, annual arthroplasty follow-
up and annual nonoperative care. Our base case for the primary to revision 1 transition 
was 2%, and the sensitivity analysis identified 2.33% as the transition for an ICER of 
$10,000/QALY. Also, if a super-obese patient has a preoperative utility greater than 0.55 
(base estimate 0.5), then it would be more cost-effective to do NM. The base case utility 
of a primary arthroplasty was 0.78, and the sensitivity analysis identified 0.83 as the 
threshold. The cost parameters identified earlier are also close to the base case. The other 
BMI group's parameters identified by the sensitivity analysis would require values 
dramatically different from the base case and would be extremely unlikely to reach those 
levels.  
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Figure 4-6: Plot of Canadian Monte Carlo Simulation of Incremental Costs and 
QALYs 
 
Figure 4-7: Percentage of Cases that Are Cost-Effective by Willingness-to-Pay 
Threshold in Canadian Monte Carlo Simulation 
The probabilistic analysis of the ICERs with the Canadian costing data demonstrated that 
in the vast majority of the simulations THA would be cost-effective compared to NM at a 
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willingness-pay-threshold of $20,000/QALY (Figures 4-6 & 4-7). A wide range of 
simulation parameters (based on the beta and gamma distributions) were used to 
demonstrate the robustness of the model. At a willingness-to-pay threshold of 
$20,000/QALY, THA was cost-effective relative to NM for 99.99% of non-obese, obese, 
and severely-obese, 99.87% of overweight, 99.83% of morbidly-obese, and 95.60% of 
super-obese. 
4.4 Discussion 
Our study results suggest that in the vast majority of cases THA would be cost-effective 
for all BMI cohorts in both the US (at a willingness-to-pay threshold of $30,000/QALY) 
and Canadian cost structures (at a willingness-to-pay threshold of $20,000/QALY). This 
raises the issue that BMI cut-offs for THA may lead to unnecessary loss of healthcare 
access. 
The expanding prevalence of obesity in the United States, Canada, and other developed 
countries is driving greater arthroplasty utilization rates.2 However, because of greater 
risks and complication rates with higher obesity levels, some surgeons are utilizing BMI 
thresholds to determine eligibility for arthroplasty.4,5 There is a greater push in this 
direction due to the bundled payments for arthroplasty in both the US and Canada. These 
bundled payments are not risk-stratified for patients.29 Morbidly-obese and super-obese 
patients have been shown to have greater costs of care than patients of lower obesity 
levels.7 In addition, surgeons and hospitals are being rated on and may be penalized due 
to their complication profile in both the US and Canada.8,9 As a result, there is pressure 
on clinicians to not offer arthroplasty to the morbidly and super-obese patients due to the 
higher 90-day costs of care. Our model suggests that at a reasonable cost, THA would 
lead to substantial improvements in quality of life for morbidly-obese and super-obese 
patients compared to NM over a 15 year time period. Healthcare economics and other 
healthcare drivers are emphasizing a focus on the short-term results and do not account 
for the long-term benefits of THA. As a result, there may be a loss of access to 
arthroplasty care for the morbidly and super-obese despite having the potential to benefit 
substantially with surgery over the longer term. 
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Bundled payment models in the US are designed such that the hospital and providers will 
need to use that fixed payment to cover all the costs of care within 90 days after surgery. 
As a result, hospitals that have an excessive number of readmissions and reoperations 
within that time window would have increased expenses without any additional 
reimbursement. This can place them at a higher risk for spending more money than they 
collect. Due to this longer time window of coverage after surgery, there has been an 
increased emphasis on perioperative management and medical optimization prior to 
surgery. For example, more surgeons are now requiring patients to quit smoking prior to 
an arthroplasty. New York University has shown improved smoking cessation results 
prior to arthroplasty with a smoking counseling program that led to improved 
postoperative complication rates.30 In the case of obesity, the major question is whether 
and to what degree obesity can be optimized prior to surgery. Some have suggested 
bariatric surgery and other weight loss measures to lower BMI level might lead to a lower 
perioperative risk profile and cost. However, there is conflicting evidence on the impact 
of bariatric surgery prior to arthroplasty. For complication rates, some suggest no 
improvement,31–33 other studies found lower complication rates,34,35 and others report 
higher complication rates.36,37 Another option is nonoperative weight loss programs. 
Unfortunately, they have not demonstrated dramatic success in weight reduction for 
morbidly or super-obese patients. Huffaker and Giori38 presented their work that showed 
only 17% of those starting above a BMI greater than 40 would reduce their BMI below 
40 in a structured weight loss program. For those patients starting at a BMI greater than 
45, less than 10% achieved the same threshold. At the same time, it is unclear if the 
patient achieved a BMI reduction below 40, whether that would lead to substantial 
improvements in their risk profile.39 In fact, one study suggests that weight loss in the 
year prior to arthroplasty had a higher risk for deep surgical site infections.33 It is thought 
that the catabolic state induced by weight loss can negatively affect wound healing and 
may explain those results. Future work examining the relationship between nutrition and 
obesity with weight loss and bariatric surgery will be critical in improving the 
preoperative risk profile for obese patients prior to an arthroplasty.40 Unfortunately to 
date, there are no protocols that have clearly demonstrated the ability to shift obese 
patients from a higher risk profile to a lower risk profile. However, for some patients, 
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weight loss alone may be sufficient to improve the symptoms of arthritis enough that an 
arthroplasty may not be needed. 
A major limitation in generalizing the results of this study is the availability of utility 
scores for patients prior to an arthroplasty. We utilized data published from a 
retrospective study of an institutional database reporting preoperative EQ-5D utility 
scores across different BMI levels.10 As a retrospective study, it is possible that patients 
with a higher BMI may have had a longer wait time for surgery, and consequently, lower 
preoperative EQ-5D scores than lower BMI patients. They found that the morbidly-obese 
had greater improvement after THA than the non-obese. Our one-way sensitivity analysis 
also identified preoperative utility as a significant parameter influencing the results of the 
model. The analysis suggested that the super-obese needed a pre-operative utility score of 
less than 0.63 to achieve an ICER value less than $25,000/QALY in the US model. We 
could not identify a utility score in the literature for the preoperative and postoperative 
utility score for the super-obese group. We used the literature on super-obese patients to 
guide an assumption of the utility scores for these patients. Our study is also limited in 
that we do not account for the associated comorbidities of higher BMI levels such as 
metabolic syndrome and cardiac risks. Certain comorbidities such as diabetes can be 
optimized preoperatively to improve outcomes after an arthroplasty. Also, this study only 
evaluated the direct medical costs of hip arthritis care and did not consider the indirect 
societal costs, which can be sizeable due to time off from work.  
The strength of our study is that it evaluates the utility of THA versus NM for a wide 
range of BMI cohorts based on the best available literature from a systematic review and 
meta-analysis, and institutional chart review. A cost-effectiveness study comparing THA 
versus NM for different BMI cohorts has not been performed previously, and this study 
adds valuable information in better balancing the long-term risks and benefits of an 
arthroplasty. Prior literature has placed too much emphasis on the short-term results, and 
we hope our results draw attention to the impact over a longer time span. 
In conclusion, THA is a very effective procedure to improve quality of life for patients of 
all BMI levels. In the vast majority of scenarios for both US and Canadian costs, we 
75 
 
found that THA was likely to be cost-effective compared to nonoperative care among all 
BMI cohorts. Currently, there are no clear ways to improve the risk profile of obese 
patients. As we continue to evaluate options to optimize the health of the morbidly and 
super-obese, these patients should not be denied a THA, since the procedure can 
dramatically improve their quality of life.  
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Chapter 5  
5 Conclusion 
5.1 Rationale for Study 
Healthcare payers in Canada, and an increasing percentage of  the United States, provide 
funding for arthroplasty surgeries with a simple bundled payment for an episode of care, 
with no risk stratification. Concurrently, both hospitals and surgeons are increasingly 
rated on their short-term arthroplasty complication rates along with other quality metrics. 
If a hospital or surgeon is reported to have higher complications, there is the potential to 
be penalized with lower funding levels and fewer patient visits. These factors are 
incentivizing surgeons to avoid operating on patients who may be at higher risk of 
perioperative complications and/or have a higher cost of care. This situation can lead to 
certain populations, who may have significant long term benefit from arthroplasty, losing 
access to care because they have higher short-term costs and complications. 
One population that is being affected by this situation are obese patients. Patients with a 
BMI higher than 40 undergoing hip and knee arthroplasty have higher costs of care and 
complications compared to non-obese patients, with the risk increasing as BMI increases. 
Because of this, some surgeons in Canada, the US, and Europe, have established BMI 
thresholds ranging from 35-45, above which they will not offer arthroplasty as a 
treatment option. Nonetheless, at mid-term follow up, patients at all BMI levels have 
comparable improvements in function with arthroplasty. This begs the important question 
as to whether we are unfairly discriminating against patients at higher BMI levels by 
denying them surgery on the basis of their weight. 
We decided to approach this study by performing a cost-effectiveness analysis to better 
weigh the risks and benefits of a THA versus nonoperative care for patients of all BMI 
levels over a 15-year time period. To determine the parameters for our model we 
performed a systematic review and meta-analysis (Chapter 2) and an institutional chart 
review (Chapter 3). We used this information to construct an economic model (Chapter 
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4) and determine the incremental cost-effectiveness ratio of THA versus nonoperative 
care. 
5.2 Summary of Findings 
In Chapter 2 and 3, we found similar results between the literature and our institutional 
registry. At a BMI threshold of 40, the risk for revision surgery increases exponentially, 
while the BMI levels lower than that have a comparable risk of revision. The costs also 
increase dramatically at a BMI level of 40 and above. Despite this, all the BMI cohorts 
demonstrated comparable improvements in their function as measured by clinical 
outcome scores.  
We applied the risks and benefits that were quantified in Chapter 2 and 3 to an economic 
model comparing THA versus nonoperative management in Chapter 4. We applied the 
BMI specific parameters from our systematic review and institution's registry and chart 
review for the analysis. The results were analyzed with both US and Canadian costs over 
a 15 year time period. We found that in both health care systems that performing a THA 
would be cost-effective relative to nonoperative management for all BMI cohorts 
5.3 Challenges  
There were several challenges that were encountered during the course of the study. One 
of the major limitations of the systematic review and meta-analysis was the dearth of high 
quality studies on the topic. We identified only 2 prospective studies that met our 
inclusion criteria, and 31 retrospective studies. The small number of internally valid 
studies has the potential to limit the quality of the results. Further, several studies 
combined the results for both THA and TKA. Since the impact of obesity on THA and 
TKA can differ owing to the differential fat distribution between the hip and the knee, we 
elected to exclude those studies that did not provide separate results for THAs. Some 
studies reported results only in a graph. The corresponding authors were contacted for 
detailed information from the graph. If the information, was not provided, the numbers 
were approximated from the graphs in the paper. Another common way of reporting 
results was using a linear regression to determine the degree of association between BMI 
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and complications. However, the relationship between BMI and complications is not a 
linear relationship as we demonstrated in Chapter 2 and 3. Below a BMI of 40, there 
generally is not much change in the risk profiles for THA patients. However, above a 
BMI of 40, the risks rise rapidly. Consequently, we elected to include those studies that 
divided BMI into categories and provided the event rates for reoperations, aseptic, and 
septic revisions rather than odds ratios for these complications.  
In Chapter 3, we examined our institutional database to obtain the 90-day costs of care 
categorized by BMI for our model. We aimed to include a cohort with a BMI greater than 
50, but our database had too few patients meeting this criteria. As a result, we adjusted 
our largest BMI cohort to be greater than 45, this allowed for the inclusion of  33 patients 
in that cohort.  
With our economic model (Chapter 4), our model may overly simplify the care and 
outcomes of a patient with hip arthritis. Our nonoperative model does not account for 
pharmaceutical, weight loss, physical therapy, and other options. However, most patients 
would have attempted one if not more of these options prior to being considered for a 
THA. As a result, our model assumed that these options were maximized prior to entering 
the decision tree. The operative side of the model simplifies the possible states to 
assuming that they have a well functioning arthroplasty or they undergo a revision. There 
are many cases where a patient has a suboptimal improvement with the arthroplasty, but 
they do not undergo a revision.  
5.4 Future Studies 
Our study highlights that the benefits of an arthroplasty outweigh the risks over a 15-year 
time period for all BMI cohorts. However, it is clear that the risks rise significantly for 
those patients with a BMI greater than 40. A prospective well-designed study could 
account for any biases in selection and improve the confidence in our results. 
It will be important in the future to focus on identifying techniques to improve the 
perioperative risk profile of patients with a BMI greater than 40. As we noted in prior 
chapters, current attempts at bariatric surgery and weight loss have not clearly 
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demonstrated improvement of the risks. Nonetheless, we should continue to focus on 
improving the risk profile. Perioperative optimization of morbid or super-obesity could 
decrease the risk, and future cost-effectiveness analysis could help quantify the value 
gained from these interventions for optimization. 
5.5 Clinical Implications  
The results of this study will hopefully be applied to realign the incentives in arthroplasty 
care in both Canada and the US. The current system in both countries places an 
inordinate emphasis on the short-term outcomes and costs of an arthroplasty. This could 
lead to an unnecessary loss of arthroplasty access for patients who have a BMI greater 
than 40. Our study highlights that the longer-term benefits of an arthroplasty outweigh 
the short-term risks and costs. It is our hope that policy makers use this information to 
adjust incentives around arthroplasty such that patients are not denied access to care. 
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